<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Antimicrob Chemother</journal-id><journal-id journal-id-type="iso-abbrev">J Antimicrob Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">748</journal-id><journal-id journal-id-type="pmc-domain">jac</journal-id><journal-id journal-id-type="publisher-id">jac</journal-id><journal-title-group><journal-title>Journal of Antimicrobial Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0305-7453</issn><issn pub-type="epub">1460-2091</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9890216</article-id><article-id pub-id-type="pmcid-ver">PMC9890216.1</article-id><article-id pub-id-type="pmcaid">9890216</article-id><article-id pub-id-type="pmcaiid">9890216</article-id><article-id pub-id-type="pmid">36473954</article-id><article-id pub-id-type="doi">10.1093/jac/dkac402</article-id><article-id pub-id-type="publisher-id">dkac402</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00740</subject><subject>AcademicSubjects/MED00290</subject><subject>AcademicSubjects/MED00230</subject></subj-group></article-categories><title-group><article-title>Oral ciprofloxacin activity against ceftriaxone-resistant <italic toggle="yes">Escherichia coli</italic> in an <italic toggle="yes">in vitro</italic> bladder infection model</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6590-6127</contrib-id><name name-style="western"><surname>Abbott</surname><given-names initials="IJ">Iain J</given-names></name><aff>
<institution>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University</institution>, <addr-line>Melbourne, Victoria</addr-line>, <country country="AU">Australia</country></aff><xref rid="dkac402-cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Gorp</surname><given-names initials="E">Elke</given-names></name><aff>
<institution>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University</institution>, <addr-line>Melbourne, Victoria</addr-line>, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cottingham</surname><given-names initials="H">Hugh</given-names></name><aff>
<institution>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University</institution>, <addr-line>Melbourne, Victoria</addr-line>, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7905-628X</contrib-id><name name-style="western"><surname>Macesic</surname><given-names initials="N">Nenad</given-names></name><aff>
<institution>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University</institution>, <addr-line>Melbourne, Victoria</addr-line>, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2392-9854</contrib-id><name name-style="western"><surname>Wallis</surname><given-names initials="SC">Steven C</given-names></name><aff>
<institution>University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland</institution>, <addr-line>Brisbane</addr-line>, <country country="AU">Australia</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6218-435X</contrib-id><name name-style="western"><surname>Roberts</surname><given-names initials="JA">Jason A</given-names></name><aff>
<institution>University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland</institution>, <addr-line>Brisbane</addr-line>, <country country="AU">Australia</country></aff><aff>
<institution>Department of Intensive Care Medicine and Pharmacy Department, Royal Brisbane and Women&#8217;s Hospital</institution>, <addr-line>Brisbane</addr-line>, <country country="AU">Australia</country></aff><aff>
<institution>Division of Anaesthesiology Critical Care Emergency and Pain Medicine, N&#238;mes University Hospital, University of Montpellier</institution>, <addr-line>N&#238;mes</addr-line>, <country country="FR">France</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8869-1509</contrib-id><name name-style="western"><surname>Meletiadis</surname><given-names initials="J">Joseph</given-names></name><aff>
<institution>Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Haidari</institution>, <addr-line>Athens</addr-line>, <country country="GR">Greece</country></aff><xref rid="dkac402-FM1" ref-type="author-notes"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2296-2126</contrib-id><name name-style="western"><surname>Peleg</surname><given-names initials="AY">Anton Y</given-names></name><aff>
<institution>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University</institution>, <addr-line>Melbourne, Victoria</addr-line>, <country country="AU">Australia</country></aff><aff>
<institution>Infection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University</institution>, <addr-line>Clayton, VIC</addr-line>, <country country="AU">Australia</country></aff><xref rid="dkac402-FM1" ref-type="author-notes"/></contrib></contrib-group><author-notes><corresp id="dkac402-cor1">Corresponding author. E-mail: <email>iain.abbott@monash.edu</email></corresp><fn id="dkac402-FM1"><p>Joseph Meletiadis and Anton Y Peleg Joint senior author</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2023</year></pub-date><pub-date pub-type="epub" iso-8601-date="2022-12-07"><day>07</day><month>12</month><year>2022</year></pub-date><volume>78</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">427877</issue-id><fpage>397</fpage><lpage>410</lpage><history><date date-type="received"><day>01</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>03</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>02</day><month>02</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-02-03 00:11:19.060"><day>03</day><month>02</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dkac402.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dkac402.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Objectives</title><p>Pharmacodynamic profiling of oral ciprofloxacin dosing for urinary tract infections caused by ceftriaxone-resistant <italic toggle="yes">Escherichia coli</italic> isolates with ciprofloxacin MIC&#8202;&#8805;&#8202;0.25 mg/L.</p></sec><sec id="s2"><title>Background</title><p>Urine-specific breakpoints for ciprofloxacin do not exist. However, high urinary concentrations may promote efficacy in isolates with low-level resistance.</p></sec><sec id="s3"><title>Methods</title><p>Ceftriaxone-resistant <italic toggle="yes">E. coli</italic> urinary isolates were screened for ciprofloxacin susceptibility. Fifteen representative strains were selected and tested using a dynamic bladder infection model. Oral ciprofloxacin dosing was simulated over 3 days (250 mg daily, 500 mg daily, 250 mg 12 hourly, 500 mg 12 hourly and 750 mg 12 hourly). The model was run for 96 h. Primary endpoint was change in bacterial density at 72 h. Secondary endpoints were follow-up change in bacterial density at 96 h and area-under-bacterial-kill-curve. Bacterial response was related to exposure (AUC<sub>0&#8211;24</sub>/MIC; <italic toggle="yes">C</italic><sub>max</sub>/MIC). PTA was determined using Monte-Carlo simulation.</p></sec><sec id="s4"><title>Results</title><p>Ninety-three clinical isolates demonstrated a trimodal ciprofloxacin MIC distribution (modal MICs at 0.016, 0.25 and 32 mg/L). Fifteen selected clinical isolates (ciprofloxacin MIC 0.25&#8211;512 mg/L) had a broad range of quinolone-resistance genes. Following ciprofloxacin exposure, <italic toggle="yes">E. coli</italic> ATCC 25922 (MIC 0.008 mg/L) was killed in all dosing experiments. Six isolates (MIC&#8202;&#8805;&#8202;16 mg/L) regrew in all experiments. Remaining isolates (MIC 0.25&#8211;8 mg/L) regrew variably after an initial period of killing, depending on simulated ciprofloxacin dose. A &gt;95% PTA, using AUC<sub>0&#8211;24</sub>/MIC targets, supported 250 mg 12 hourly for susceptible isolates (MIC&#8202;&#8804;&#8202;0.25 mg/L). For isolates with MIC&#8202;&#8804;&#8202;1 mg/L, 750 mg 12 hourly promoted 3 log<sub>10</sub> kill at the end of treatment (72 h), 1 log<sub>10</sub> kill at follow-up (96 h) and 90% maximal activity (AUBKC<sub>0&#8211;96</sub>).</p></sec><sec id="s5"><title>Conclusions</title><p>Bladder infection modelling supports oral ciprofloxacin activity against <italic toggle="yes">E. coli</italic> with low-level resistance (ciprofloxacin MIC&#8202;&#8804;&#8202;1 mg/L) when using high dose therapy (750 mg 12 hourly).</p></sec></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Australian National Health and Medical Research Council</institution></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>NHMRC</institution><institution-id institution-id-type="doi">10.13039/501100000925</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Practitioner Fellowships</institution></institution-wrap></funding-source><award-id>APP1117065</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Australian National Health and Medical Research Council for a Centre of Research Excellence</institution></institution-wrap></funding-source><award-id>APP2007007</award-id></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Investigator Grant</institution></institution-wrap></funding-source><award-id>APP2009736</award-id></award-group></funding-group><counts><page-count count="14"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="dkac402-s0"><title>Introduction</title><p>Urinary tract infections (UTIs) are extremely common.<sup><xref rid="dkac402-B1" ref-type="bibr">1</xref></sup> Severe infection accounts for 25% of emergency sepsis cases, with a 6.2% in-hospital mortality and 8.6% ICU mortality.<sup><xref rid="dkac402-B2" ref-type="bibr">2</xref></sup><italic toggle="yes">Escherichia coli</italic> remains the most common uropathogen. Antimicrobial resistance (AMR) and the global spread of the MDR strain <italic toggle="yes">E. coli</italic> ST131 and, more recently, <italic toggle="yes">E. coli</italic> ST1193, greatly limits empirical therapy in serious infections.<sup><xref rid="dkac402-B3" ref-type="bibr">3&#8211;7</xref></sup> Rates of resistance have progressively increased since 2007, with an 8-fold rise in resistance genes and increased numbers of attributable deaths and disability-adjusted life years.<sup><xref rid="dkac402-B8" ref-type="bibr">8&#8211;10</xref></sup> AMR in UTIs is the one of the leading infectious syndromes contributing to the global burden of deaths associated with resistance.<sup><xref rid="dkac402-B11" ref-type="bibr">11</xref></sup> Globally in 2019, UTIs caused by <italic toggle="yes">E. coli</italic> with antimicrobial resistance resulted in &gt;26&#8202;000 deaths directly attributable to AMR and &gt;100&#8202;000 deaths related to AMR.<sup><xref rid="dkac402-B12" ref-type="bibr">12</xref></sup> This was predominantly in <italic toggle="yes">E. coli</italic> with resistance to third-generation cephalosporins and fluoroquinolones.</p><p>Oral ciprofloxacin has excellent bioavailability and tissue penetration and achieves high concentrations in urine compared with plasma (Table <xref rid="dkac402-T1" ref-type="table">1</xref>). It has been well studied in the treatment of infections arising from the urinary tract. The US FDA and the EMA, however, provide black box warnings about the potential harms with the use of fluoroquinolones, including tendinopathy, aortic ruptures or tears and CNS effects.<sup><xref rid="dkac402-B23" ref-type="bibr">23</xref>,<xref rid="dkac402-B24" ref-type="bibr">24</xref></sup> As such, ciprofloxacin is not recommended for routine use in mild or recurrent UTIs. Alternative antibiotics with a narrower-spectrum, better side-effect profile, and less microbiome disruption are recommended to be used whenever possible, such as nitrofurantoin, fosfomycin, pivmecillinam and co-trimoxazole. The EUCAST 2022 breakpoints for ciprofloxacin are &#8216;susceptible, standard dosing regimen&#8217; (S) MIC&#8202;&#8804;&#8202;0.25, and &#8216;resistant&#8217; (R) MIC&#8202;&gt;&#8202;0.5 mg/L. An MIC measurement of 0.5 mg/L is designated as an area of technical uncertainty (ATU), dealt by the laboratory (depending on type of sample, number of alternative agents, severity of infection, consultation with clinical colleagues). Breakpoints are based on standard oral dosing of 500 mg 12 hourly, with high dose defined as 750 mg 12 hourly.<sup><xref rid="dkac402-B25" ref-type="bibr">25</xref></sup> There are no UTI-specific breakpoints. CLSI 2022 breakpoints for ciprofloxacin are &#8216;susceptible&#8217; (S) MIC&#8202;&#8804;&#8202;0.25 mg/L, &#8216;intermediate&#8217; (I) MIC&#8202;=&#8202;0.5 mg/L^, &#8216;resistant&#8217; (R) MIC&#8202;&#8805;&#8202;1 mg/L, where &#8216;^&#8217; indicates the potential to concentrate in the urine. Breakpoints are also based on oral 500 mg 12 hourly.<sup><xref rid="dkac402-B26" ref-type="bibr">26</xref></sup> The decision to report &#8216;I^&#8217; is made by each laboratory based on institution-specific guidelines and in consultation with medical personnel. A lower dose of ciprofloxacin of 250 mg 12 hourly is commonly used for uncomplicated UTIs.<sup><xref rid="dkac402-B27" ref-type="bibr">27</xref></sup></p><table-wrap position="float" id="dkac402-T1" orientation="portrait"><label>Table 1.</label><caption><p>Oral ciprofloxacin urinary pharmacokinetics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Year</th><th align="center" rowspan="1" colspan="1">Subjects</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="center" rowspan="1" colspan="1">Dose</th><th align="center" rowspan="1" colspan="1">Time (h)</th><th align="center" rowspan="1" colspan="1">Mean (mg/L)</th><th align="center" rowspan="1" colspan="1">Min</th><th align="center" rowspan="1" colspan="1">Max</th><th align="center" rowspan="1" colspan="1">% CV</th><th align="center" rowspan="1" colspan="1">Recovery in urine</th><th align="center" rowspan="1" colspan="1">Method</th><th align="center" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">1984</td><td rowspan="2" colspan="1">Healthy volunteers (all male)</td><td rowspan="2" colspan="1">12</td><td rowspan="2" colspan="1">250 mg q12; 7 days (13 doses)</td><td rowspan="1" colspan="1">0&#8211;2</td><td rowspan="1" colspan="1">&#8212;<sup><xref rid="dkac402-tblfn1" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">840</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="2" colspan="1">&#8212;</td><td rowspan="2" colspan="1">HPLC</td><td rowspan="2" colspan="1">
<sup>
<xref rid="dkac402-B13" ref-type="bibr">13</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">6&#8211;12</td><td rowspan="1" colspan="1">44.7&#8202;&#177;&#8202;25 to 68.7&#8202;&#177;&#8202;45</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">56 to 77%</td></tr><tr><td rowspan="3" colspan="1">1984</td><td rowspan="3" colspan="1">Healthy volunteers (all male)</td><td rowspan="3" colspan="1">9</td><td rowspan="3" colspan="1">250, 500, 750 mg q12; 7 days</td><td rowspan="1" colspan="1">0&#8211;2 (250 mg)<break/>2&#8211;4<break/>4&#8211;8<break/>8&#8211;12</td><td rowspan="1" colspan="1">205 to 261<break/>147 to 229<break/>90 to 101<break/>32 to 34</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;12 h (250 mg): 41%&#8202;&#177;&#8202;7% to 47%&#8202;&#177;&#8202;19%</td><td rowspan="3" colspan="1">Bioassay<sup><xref rid="dkac402-tblfn2" ref-type="table-fn">b</xref></sup></td><td rowspan="3" colspan="1">
<sup>
<xref rid="dkac402-B14" ref-type="bibr">14</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">0&#8211;2 (500 mg)<break/>2&#8211;4<break/>4&#8211;8<break/>8&#8211;12</td><td rowspan="1" colspan="1">255 to 518<break/>321 to 448<break/>117 to 199<break/>26 to 82</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;12 h (500 mg): 33%&#8202;&#177;&#8202;9% to 37%&#8202;&#177;&#8202;10%</td></tr><tr><td rowspan="1" colspan="1">0&#8211;2 (750 mg)<break/>2&#8211;4<break/>4&#8211;8<break/>8&#8211;12</td><td rowspan="1" colspan="1">243 to 846<break/>544 to 704<break/>169 to 360<break/>55 to 151</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;12 h (750 mg): 31%&#8202;&#177;&#8202;7% to 38%&#8202;&#177;&#8202;8%</td></tr><tr><td rowspan="3" colspan="1">1985</td><td rowspan="3" colspan="1">Healthy volunteers (50% female)</td><td rowspan="3" colspan="1">12</td><td rowspan="3" colspan="1">50 mg, 100 mg, 750 mg; single dose</td><td rowspan="3" colspan="1">0&#8211;3, 3&#8211;6, 6&#8211;12 &amp; 12&#8211;24</td><td rowspan="3" colspan="1">&#8212;<sup><xref rid="dkac402-tblfn1" ref-type="table-fn">a</xref></sup></td><td rowspan="3" colspan="1">&#8212;</td><td rowspan="3" colspan="1">&#8212;</td><td rowspan="3" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;24 h (50 mg): 36%&#8202;&#177;&#8202;10%</td><td rowspan="3" colspan="1">Bioassay<sup><xref rid="dkac402-tblfn3" ref-type="table-fn">c</xref></sup></td><td rowspan="3" colspan="1">
<sup>
<xref rid="dkac402-B15" ref-type="bibr">15</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">0&#8211;24 h (100 mg): 35%&#8202;&#177;&#8202;8%</td></tr><tr><td rowspan="1" colspan="1">0&#8211;24 h (750 mg): 33%&#8202;&#177;&#8202;5%</td></tr><tr><td rowspan="1" colspan="1">1985</td><td rowspan="1" colspan="1">Healthy volunteers (50% female)</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">250 mg q12; 4 days (7 doses)</td><td rowspan="1" colspan="1">&#8212;<sup><xref rid="dkac402-tblfn4" ref-type="table-fn">d</xref></sup></td><td rowspan="1" colspan="1">&#8212;<sup><xref rid="dkac402-tblfn1" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;12 h: 38%&#8202;&#177;&#8202;6% to 46%&#8202;&#177;&#8202;6% (bioassay); 26%&#8202;&#177;&#8202;5% to 30%&#8202;&#177;&#8202;9% (HPLC)</td><td rowspan="1" colspan="1">Bioassay<sup><xref rid="dkac402-tblfn5" ref-type="table-fn">e</xref></sup> and HPLC<sup><xref rid="dkac402-tblfn6" ref-type="table-fn">f</xref></sup></td><td rowspan="1" colspan="1">
<sup>
<xref rid="dkac402-B16" ref-type="bibr">16</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">1985</td><td rowspan="1" colspan="1">Healthy volunteers (all male)</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">500 mg; single dose</td><td rowspan="1" colspan="1">0&#8211;2<break/>2&#8211;4<break/>4&#8211;8<break/>8&#8211;12</td><td rowspan="1" colspan="1">464<break/>304<break/>189<break/>111</td><td rowspan="1" colspan="1">28<break/>60<break/>31<break/>19</td><td rowspan="1" colspan="1">1847<break/>1219<break/>731<break/>128</td><td rowspan="1" colspan="1">98%<break/>95%<break/>93%<break/>25%</td><td rowspan="1" colspan="1">0&#8211;12 h: 45%&#8202;&#177;&#8202;12%<break/>0&#8211;24 h: 51%&#8202;&#177;&#8202;12.2%</td><td rowspan="1" colspan="1">HPLC</td><td rowspan="1" colspan="1">
<sup>
<xref rid="dkac402-B17" ref-type="bibr">17</xref>
</sup>
</td></tr><tr><td rowspan="4" colspan="1">1986</td><td rowspan="4" colspan="1">Healthy volunteers (all male)</td><td rowspan="4" colspan="1">12</td><td rowspan="4" colspan="1">250, 500, 750, 1000 mg; single dose</td><td rowspan="1" colspan="1">0&#8211;2 (250 mg)<break/>2&#8211;4<break/>4&#8211;8<break/>8&#8211;12</td><td rowspan="1" colspan="1">190<sup><xref rid="dkac402-tblfn7" ref-type="table-fn">g</xref></sup><break/>180<break/>90<break/>40</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;48 h (250 mg): 36%&#8202;&#177;&#8202;12%</td><td rowspan="4" colspan="1">Bioassay<sup><xref rid="dkac402-tblfn2" ref-type="table-fn">b</xref></sup></td><td rowspan="4" colspan="1">
<sup>
<xref rid="dkac402-B18" ref-type="bibr">18</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">0&#8211;2 (500 mg)<break/>2&#8211;4<break/>4&#8211;8<break/>8&#8211;12</td><td rowspan="1" colspan="1">340<sup><xref rid="dkac402-tblfn7" ref-type="table-fn">g</xref></sup><break/>400<break/>220<break/>120</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;48 h (500 mg): 44%&#8202;&#177;&#8202;7.5%</td></tr><tr><td rowspan="1" colspan="1">0&#8211;2 (750 mg)<break/>2&#8211;4<break/>4&#8211;8<break/>8&#8211;12</td><td rowspan="1" colspan="1">460<sup><xref rid="dkac402-tblfn7" ref-type="table-fn">g</xref></sup><break/>530<break/>280<break/>200</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;48 h (750 mg): 40%&#8202;&#177;&#8202;12.2%</td></tr><tr><td rowspan="1" colspan="1">0&#8211;2 (1000 mg)<break/>2&#8211;4<break/>4&#8211;8<break/>8&#8211;12</td><td rowspan="1" colspan="1">390<sup><xref rid="dkac402-tblfn7" ref-type="table-fn">g</xref></sup><break/>400<break/>240<break/>130</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;48 h (1000 mg): 29%&#8202;&#177;&#8202;10%</td></tr><tr><td rowspan="1" colspan="1">1994</td><td rowspan="1" colspan="1">Healthy volunteers (all male)</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">750 mg; single dose</td><td rowspan="1" colspan="1">0&#8211;4, 4&#8211;8, 8&#8211;12, 12&#8211;24</td><td rowspan="1" colspan="1">&#8212;<sup><xref rid="dkac402-tblfn1" ref-type="table-fn">a</xref>,<xref rid="dkac402-tblfn8" ref-type="table-fn">h</xref></sup></td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">0&#8211;12 h: 41% (bioassay); 36% (HPLC)</td><td rowspan="1" colspan="1">Bioassay<sup><xref rid="dkac402-tblfn5" ref-type="table-fn">e</xref></sup> and HPLC<sup><xref rid="dkac402-tblfn6" ref-type="table-fn">f</xref></sup></td><td rowspan="1" colspan="1">
<sup>
<xref rid="dkac402-B19" ref-type="bibr">19</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">2003</td><td rowspan="1" colspan="1">Healthy volunteers (50% female)</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">500 mg; single dose</td><td rowspan="1" colspan="1">0&#8211;6<break/>6&#8211;12</td><td rowspan="1" colspan="1">407<break/>47</td><td rowspan="1" colspan="1">23<break/>19</td><td rowspan="1" colspan="1">733<break/>76</td><td rowspan="1" colspan="1">44%<break/>30%</td><td rowspan="1" colspan="1">0&#8211;12 h: 37%&#8202;&#177;&#8202;10%</td><td rowspan="1" colspan="1">HPLC</td><td rowspan="1" colspan="1">
<sup>
<xref rid="dkac402-B20" ref-type="bibr">20</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">Healthy volunteers (50% female)</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">500 mg; single dose</td><td rowspan="1" colspan="1">0&#8211;6<break/>6&#8211;12</td><td rowspan="1" colspan="1">368<break/>77</td><td rowspan="1" colspan="1">100<break/>30</td><td rowspan="1" colspan="1">1000<break/>179</td><td rowspan="1" colspan="1">61%<break/>48%</td><td rowspan="1" colspan="1">0&#8211;12 h: 32%&#8202;&#177;&#8202;10%</td><td rowspan="1" colspan="1">HPLC</td><td rowspan="1" colspan="1">
<sup>
<xref rid="dkac402-B21" ref-type="bibr">21</xref>
</sup>
</td></tr><tr><td rowspan="1" colspan="1">2006</td><td rowspan="1" colspan="1">Healthy volunteers (50% female)</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">500 mg; single dose</td><td rowspan="1" colspan="1">0&#8211;6<break/>6&#8211;12</td><td rowspan="1" colspan="1">268<break/>60</td><td rowspan="1" colspan="1">130<break/>25</td><td rowspan="1" colspan="1">967<break/>76</td><td rowspan="1" colspan="1">78%<break/>21%</td><td rowspan="1" colspan="1">0&#8211;12 h: 34%&#8202;&#177;&#8202;8%</td><td rowspan="1" colspan="1">HPLC</td><td rowspan="1" colspan="1">
<sup>
<xref rid="dkac402-B22" ref-type="bibr">22</xref>
</sup>
</td></tr></tbody></table><table-wrap-foot><fn id="dkac402-tblfn1"><p>Average urinary concentrations not provided.</p></fn><fn id="dkac402-tblfn2"><p>
<italic toggle="yes">Klebsiella pneumoniae</italic> ATCC 10031.</p></fn><fn id="dkac402-tblfn3"><p>
<italic toggle="yes">K. pneumoniae</italic> ATCC 10031 for concentrations &lt;0.15 mg/L and <italic toggle="yes">Bacillus subtilis</italic> ATCC 6633 for concentrations &gt;0.15 mg/L.</p></fn><fn id="dkac402-tblfn4"><p>Urine collected at seven time intervals after the first and seventh doses. Average urinary concentrations not provided.</p></fn><fn id="dkac402-tblfn5"><p>
<italic toggle="yes">E. coli</italic> 4004.</p></fn><fn id="dkac402-tblfn6"><p>Bioassay results higher than HPLC, supporting the assumption that microbiologically active metabolites are excreted renally.</p></fn><fn id="dkac402-tblfn7"><p>Average urinary concentrations were only presented in graphical form; measurements are approximated from the figure.</p></fn><fn id="dkac402-tblfn8"><p>Authors state that urinary concentrations were &gt;26 mg/L from all 12&#8211;24 urine samples.</p></fn></table-wrap-foot></table-wrap><p>A recent systematic review highlights the global rising rates of fluoroquinolone-resistant <italic toggle="yes">E. coli</italic> in community-acquired uncomplicated UTIs in women, with resistance rate rising from 0.5% to 15.3% in the UK, 8.7% to 15.1% in Germany, 22.9% to 30.8% in Spain, 4% to 12% in North America, and 25% to &gt;40% in Asia.<sup><xref rid="dkac402-B28" ref-type="bibr">28</xref></sup> Given high urinary concentrations achieved after oral dosing, it is hypothesized that urinary isolates categorized as ciprofloxacin resistant could still be effectively treated with high-dose ciprofloxacin. We have performed pharmacodynamic profiling of different oral ciprofloxacin dosing schedules within a dynamic bladder infection <italic toggle="yes">in vitro</italic> model to assess the applicability of UTI-specific ciprofloxacin breakpoints against ceftriaxone-resistant <italic toggle="yes">E. coli</italic> urinary isolates.</p></sec><sec sec-type="methods" id="dkac402-s1"><title>Methods</title><sec id="dkac402-s1.1"><title>Media</title><p>Cation-adjusted Mueller-Hinton II agar (MHA, BD, USA), CAMHB (BD), pooled human urine and synthetic human urine (SHU) were used. Human urine was collected and pooled from healthy female volunteers and filter sterilized (Ethics Committee approval: Project no. 27033). SHU was modified (mSHU) from a previous study<sup><xref rid="dkac402-B29" ref-type="bibr">29</xref></sup> with addition of 0.1% v/v yeast extract (stock solution 10% w/v) to best match <italic toggle="yes">E. coli</italic> growth in urine (Table <xref rid="sup1" ref-type="supplementary-material">S1</xref> and Figure <xref rid="sup1" ref-type="supplementary-material">S1</xref>, available as <xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> at <italic toggle="yes">JAC</italic> Online). SHU and mSHU were adjusted to pH 5.6.</p></sec><sec id="dkac402-s1.2"><title>E. coli isolates and susceptibility testing</title><p>Clinical, non-duplicate <italic toggle="yes">E. coli</italic> isolates from a urinary source that were ceftriaxone resistant were selected from a surveillance collection at a tertiary acute care hospital (Ethics Committee approval: Project no. 533/16). Isolates underwent ciprofloxacin susceptibility testing by broth microdilution (BMD).<sup><xref rid="dkac402-B30" ref-type="bibr">30</xref></sup> Fifteen clinical isolates, and <italic toggle="yes">E. coli</italic> ATCC 25922, were selected to reflect a range of ciprofloxacin MIC values. Ciprofloxacin MICs were repeated in triplicate by BMD in CAMHB and mSHU, and tested in pooled human urine as a single replicate. WGS was performed determining ST, phylogenetic relatedness, quinolone-resistance determinants and &#946;-lactamase genes (see Supplementary Methods).</p></sec><sec id="dkac402-s1.3"><title>Bladder infection in vitro model</title><p>A multicompartment infection model applying a continuous dilution system was used with mSHU as the liquid medium (Figure <xref rid="dkac402-F1" ref-type="fig">1</xref>).<sup><xref rid="dkac402-B31" ref-type="bibr">31</xref></sup> Sixteen bladder compartments were run in parallel. Medium was run at a continuous flow rate of 400 mL/h from fresh media reservoirs into the &#8216;intestinal&#8217; compartment containing ciprofloxacin (Aspen Pharmacare Australia, 200 mg/100 mL; volume 300&#8211;900 mL), and then into the &#8216;circulatory&#8217; compartment (volume 1450 mL). The volumes of these two compartments were kept static for the duration of each experiment. Medium flow into each individual bladder compartment was 25 mL/h. Normal human urodynamics was simulated. Volume in each bladder increased over time prior to an intermittent voiding schedule that reduced the volume to a residual 5 mL. First void was 2 h after starting and continued 4 hourly thereafter. Each bladder was inoculated with an <italic toggle="yes">E. coli</italic> isolate with 10 mL of 10<sup>6</sup> cfu/mL, providing a total bacterial count equivalent to human UTIs (i.e. &#8805;10<sup>5</sup> cfu/mL in 200 mL void). Ciprofloxacin MICs were rechecked from the starting inoculum and if an isolate regrew at the completion of an experiment.</p><fig position="float" id="dkac402-F1" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>Bladder infection model. <italic toggle="yes">In vitro</italic> model set-up of the dynamic multicompartment dilution model used for the simulation urinary ciprofloxacin exposure following oral dosing. This figure appears in colour in the online version of <italic toggle="yes">JAC</italic> and in black and white in the print version of <italic toggle="yes">JAC</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dkac402f1.jpg"/></fig></sec><sec id="dkac402-s1.4"><title>Quantification of bacterial growth</title><p>Bacterial density (cfu/mL) was first assessed under drug-free conditions over 24 h. During ciprofloxacin exposure over 3 days, bacterial density was measured at 0, 6, 24, 30, 48, 54 h and at the end of treatment (72 h). A follow-up bacterial density was measured at 96 h. Pharmacodynamic (PD) samples were collected directly from each bladder compartment. To negate antibiotic carry-over, a centrifuge/wash process was performed twice, reducing ciprofloxacin concentrations 100-fold. Bacterial loss was minimal (&lt;0.1 log<sub>10</sub> cfu/mL). Samples were serially diluted and 20 &#181;L from each dilution plated onto MHA. Emergence of resistance was identified by plating in parallel onto MHA with 2 mg/L and 128 mg/L ciprofloxacin (every 24 h). Plates were incubated aerobically, 35&#176;C&#8202;&#177;&#8202;1&#176;C for 16&#8211;20 h. Plates with ciprofloxacin were reincubated for an additional 24 h. Limit of detection was 50 cfu/mL.</p></sec><sec id="dkac402-s1.5"><title>Simulated ciprofloxacin urinary exposure</title><p>Human urinary ciprofloxacin concentrations after oral dosing (Table <xref rid="dkac402-T1" ref-type="table">1</xref>) were used as targets for the <italic toggle="yes">in vitro</italic> model.<sup><xref rid="dkac402-B13" ref-type="bibr">13&#8211;22</xref></sup> Drug distribution equations were used to inform <italic toggle="yes">in vitro</italic> flow rate, volumes and ciprofloxacin dosage to achieve the target concentrations and a calculated AUC<sub>0&#8211;24</sub>.<sup><xref rid="dkac402-B32" ref-type="bibr">32</xref></sup> Dosing schedules were administered as a 3 day course. Target exposures [peak concentration (<italic toggle="yes">C</italic><sub>max</sub>], trough concentration (<italic toggle="yes">C</italic><sub>min</sub>) and calculated AUC<sub>0&#8211;24</sub> on the third day of treatment were as follows: 250 mg daily (<italic toggle="yes">C</italic><sub>max</sub> 220 mg/L, <italic toggle="yes">C</italic><sub>min</sub> 1 mg/L, AUC<sub>0&#8211;24</sub> 1444 mg&#183;h/L), 500 mg daily (<italic toggle="yes">C</italic><sub>max</sub> 398 mg/L, <italic toggle="yes">C</italic><sub>min</sub> 3 mg/L, AUC<sub>0&#8211;24</sub> 2969 mg&#183;h/L), 250 mg 12 hourly (<italic toggle="yes">C</italic><sub>max</sub> 232 mg/L, <italic toggle="yes">C</italic><sub>min</sub> 30 mg/L, AUC<sub>0&#8211;24</sub> 2880 mg&#183;h/L), 500 mg 12 hourly (<italic toggle="yes">C</italic><sub>max</sub> 426 mg/L, <italic toggle="yes">C</italic><sub>min</sub> 79 mg/L, AUC<sub>0&#8211;24</sub> 5937 mg&#183;h/L), 750 mg 12 hourly (<italic toggle="yes">C</italic><sub>max</sub> 579 mg/L, <italic toggle="yes">C</italic><sub>min</sub> 154 mg/L, AUC<sub>0&#8211;24</sub> 8969 mg&#183;h/L). Greater than 90% of each administered dose was excreted by 12 h.</p></sec><sec id="dkac402-s1.6"><title>Measurement of ciprofloxacin concentrations</title><p>Representative pharmacokinetic (PK) samples were collected from three bladder compartments at <italic toggle="yes">C</italic><sub>max</sub> and <italic toggle="yes">C</italic><sub>min</sub> each day of dosing, and at the completion of each experiment. All 16 bladder compartments were sampled at the <italic toggle="yes">C</italic><sub>max</sub> on the third day. Interday and intercompartment variability was assessed by the average relative standard deviation. Samples were filtered, stored at &#8722;80&#176;C and batched for testing. Ciprofloxacin concentrations were measured by a UHPLC with fluorometric detection (UHPLC-Fl) method on a Nexera2 liquid chromatograph connected to an RF-20Axs fluorescence detector (Shimadzu, Kyoto, Japan). Calibration range was 0.1 to 1000 mg/L. The precision (6.9%, 6.4%, 4.3% and 1.4%) and accuracy (0.9%, 5.0%, 10.%5 and &#8722;2.2% at 3, 30, 300 and 1000 mg/L) met FDA guidance.<sup><xref rid="dkac402-B33" ref-type="bibr">33</xref></sup> Ciprofloxacin was stable when incubated in SHU, with 0.2%, 1.9% and 4.6% reduction in the measured concentration at 24, 48 and 72 h, respectively. Linear regression and Bland&#8211;Altman plots quantified the accuracy and bias of the measured concentrations compared to target.</p></sec><sec id="dkac402-s1.7"><title>PK/PD analysis</title><p>Primary endpoint was end-of-treatment (72 h) change in bacterial density. Secondary endpoints were change in bacterial density at follow-up (96 h), and total bacterial response measured by the area under the bacterial kill curve (AUBKC<sub>0&#8211;96</sub>). The relationship between ciprofloxacin exposure (AUC<sub>0&#8211;24</sub>/MIC and <italic toggle="yes">C</italic><sub>max</sub>/MIC) and bacterial response was assessed using an <italic toggle="yes">E</italic><sub>max</sub> non-linear regression model. No constraints were applied, unless indicated. Goodness of fit was assessed by visual inspection, residuals analysis and R<sup>2</sup>. Exposures required for stasis, 1, 2 and 3 log<sub>10</sub> kill, and 50% (EI<sub>50</sub>) and 90% (EI<sub>90</sub>) of the maximum effect was determined. This analysis was repeated using MIC measurements by BMD in mSHU. Monte Carlo simulations (MCS), using the &#8216;normal random number generator&#8217; for 5000 patients (Microsoft<sup>&#174;</sup> Excel for Mac, v16.63) was used to determine PTA for each ciprofloxacin dosing regimen, with &#177;50% allowance for variability in human urinary concentrations. Protein binding in urine is minimal. All data were analysed using GraphPad Prism (version 9.4.1 macOS).</p></sec></sec><sec sec-type="results" id="dkac402-s2"><title>Results</title><sec id="dkac402-s2.1"><title>E. coli isolates</title><p>Ninety-three ceftriaxone-resistant <italic toggle="yes">E. coli</italic> clinical urinary isolates were selected for ciprofloxacin MIC testing. A trimodal MIC distribution was observed with modal MICs at 0.016, 0.25 and 32 mg/L (Figure <xref rid="dkac402-F2" ref-type="fig">2</xref>). Most isolates (86%) demonstrated a ciprofloxacin MIC higher than the epidemiological cut-off (ECOFF) of 0.064 mg/L.<sup><xref rid="dkac402-B34" ref-type="bibr">34</xref></sup> Clinical isolates selected for additional testing had ciprofloxacin MICs ranging from 0.25 to 512 mg/L (Table <xref rid="dkac402-T2" ref-type="table">2</xref>). Compared with standard testing in CAMHB, ciprofloxacin MIC measurements were, on average, 4 (&#177;1) log<sub>2</sub> dilutions higher when tested in mSHU and in pooled human urine. Isolates reflected a diverse range of STs and were not members of a transmission cluster (&gt;45 SNPs between all five <italic toggle="yes">E. coli</italic> ST131). All isolates with ciprofloxacin MIC&#8202;&#8805;&#8202;4 mg/L had <italic toggle="yes">parC</italic> S80I mutation (Table <xref rid="dkac402-T2" ref-type="table">2</xref>). Sequence reads were deposited in the NCBI Sequence Read Archive (Table <xref rid="sup1" ref-type="supplementary-material">S2</xref>).</p><fig position="float" id="dkac402-F2" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>Ciprofloxacin MIC distribution of ceftriaxone-resistant <italic toggle="yes">E. coli</italic> urinary isolates. <italic toggle="yes">E. coli</italic> urinary isolates (<italic toggle="yes">n</italic>&#8202;=&#8202;93). MIC testing performed by BMD. WT isolates defined by MIC&#8202;&#8804;&#8202;0.064 mg/L. Susceptibility categories as per EUCAST 2022 breakpoint table. This figure appears in colour in the online version of <italic toggle="yes">JAC</italic> and in black and white in the print version of <italic toggle="yes">JAC</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dkac402f2.jpg"/></fig><table-wrap position="float" id="dkac402-T2" orientation="portrait"><label>Table 2.</label><caption><p>Ceftriaxone-resistant <italic toggle="yes">E. coli</italic> isolates tested in the bladder infection model</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Isolate #</th><th align="center" colspan="3" rowspan="1">Ciprofloxacin MIC, mg/L (range)</th><th align="center" rowspan="2" colspan="1">ST</th><th align="center" rowspan="2" colspan="1">QRDRs</th><th align="center" rowspan="2" colspan="1">Plasmid-mediated quinolone resistance</th><th align="center" rowspan="2" colspan="1">Multidrug- efflux-pump regulator</th><th align="center" rowspan="2" colspan="1">&#946;-Lactamase</th></tr><tr><th align="center" rowspan="1" colspan="1">CAMHB</th><th align="center" rowspan="1" colspan="1">mSHU</th><th align="center" rowspan="1" colspan="1">Urine</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">25922</td><td rowspan="1" colspan="1">0.008 (0.008)</td><td rowspan="1" colspan="1">0.125 (0.125)</td><td rowspan="1" colspan="1">0.0625</td><td rowspan="1" colspan="1">73</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">057</td><td rowspan="1" colspan="1">0.25 (0.25)</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">131</td><td rowspan="1" colspan="1">gyrA_S83L<break/>parE_I529L</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-27</td></tr><tr><td rowspan="1" colspan="1">017</td><td rowspan="1" colspan="1">0.5 (0.25&#8211;0.5)</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">219</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">qnrS1</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-15</td></tr><tr><td rowspan="1" colspan="1">014</td><td rowspan="1" colspan="1">0.5 (0.25&#8211;0.5)</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">gyrA_S83L</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-14</td></tr><tr><td rowspan="1" colspan="1">015</td><td rowspan="1" colspan="1">0.5 (0.5)</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">131</td><td rowspan="1" colspan="1">gyrA_S83L<break/>parC_A108V<break/>parE_I529L</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-27</td></tr><tr><td rowspan="1" colspan="1">016</td><td rowspan="1" colspan="1">0.5 (0.5)</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">131</td><td rowspan="1" colspan="1">gyrA_S83L<break/>parE_I529L parE_S458A</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-14</td></tr><tr><td rowspan="1" colspan="1">019</td><td rowspan="1" colspan="1">1 (1)</td><td rowspan="1" colspan="1">16 (16)</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">10320</td><td rowspan="1" colspan="1">gyrA_S83L<break/>parE_S458A</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-15</td></tr><tr><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1">4 (4&#8211;8)</td><td rowspan="1" colspan="1">256 (256)</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">2599</td><td rowspan="1" colspan="1">gyrA_S83L gyrA_D87N<break/>parC_S80I</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-15</td></tr><tr><td rowspan="1" colspan="1">132</td><td rowspan="1" colspan="1">8 (4&#8211;8)</td><td rowspan="1" colspan="1">64 (64)</td><td rowspan="1" colspan="1">128</td><td rowspan="1" colspan="1">648</td><td rowspan="1" colspan="1">gyrA_S83L<break/>parC_S80I<break/>parE_S458A</td><td rowspan="1" colspan="1">qnrS1</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-65</td></tr><tr><td rowspan="1" colspan="1">104</td><td rowspan="1" colspan="1">8 (8)</td><td rowspan="1" colspan="1">256 (256)</td><td rowspan="1" colspan="1">256</td><td rowspan="1" colspan="1">95</td><td rowspan="1" colspan="1">gyrA_S83L gyrA_D87N<break/>parC_S80I</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">marR_S3N</td><td rowspan="1" colspan="1">CTX-M-55</td></tr><tr><td rowspan="1" colspan="1">093</td><td rowspan="1" colspan="1">16 (16)</td><td rowspan="1" colspan="1">512 (512)</td><td rowspan="1" colspan="1">512</td><td rowspan="1" colspan="1">1193</td><td rowspan="1" colspan="1">gyrA_S83L gyrA_D87N<break/>parC_S80I<break/>parE_L416F</td><td rowspan="1" colspan="1">qnrS1<sup><xref rid="dkac402-tblfn10" ref-type="table-fn">a</xref></sup></td><td rowspan="1" colspan="1">marR_S3N</td><td rowspan="1" colspan="1">CTX-M-14</td></tr><tr><td rowspan="1" colspan="1">124</td><td rowspan="1" colspan="1">32 (32)</td><td rowspan="1" colspan="1">512 (512)</td><td rowspan="1" colspan="1">&gt;512</td><td rowspan="1" colspan="1">131</td><td rowspan="1" colspan="1">gyrA_S83L gyrA_D87N<break/>parC_S80I parC_E84V<break/>parE_I529L</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-15</td></tr><tr><td rowspan="1" colspan="1">096</td><td rowspan="1" colspan="1">32 (32)</td><td rowspan="1" colspan="1">512 (512)</td><td rowspan="1" colspan="1">&gt;512</td><td rowspan="1" colspan="1">410</td><td rowspan="1" colspan="1">gyrA_S83L gyrA_D87N<break/>parC_S80I<break/>parE_S458A</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-15 CMY-42</td></tr><tr><td rowspan="1" colspan="1">127</td><td rowspan="1" colspan="1">64 (64)</td><td rowspan="1" colspan="1">&gt;512 (&gt;512)</td><td rowspan="1" colspan="1">&gt;512</td><td rowspan="1" colspan="1">457</td><td rowspan="1" colspan="1">gyrA_S83L gyrA_D87Y<break/>parC_S80I<break/>parE_S458A</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CMY-2</td></tr><tr><td rowspan="1" colspan="1">139</td><td rowspan="1" colspan="1">128 (128)</td><td rowspan="1" colspan="1">512 (512)</td><td rowspan="1" colspan="1">&gt;512</td><td rowspan="1" colspan="1">131</td><td rowspan="1" colspan="1">gyrA_S83L gyrA_D87N<break/>parC_S80I parC_E84V<break/>parE_I529L</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">CTX-M-15</td></tr><tr><td rowspan="1" colspan="1">087</td><td rowspan="1" colspan="1">512 (512)</td><td rowspan="1" colspan="1">&gt;512 (&gt;512)</td><td rowspan="1" colspan="1">&gt;512</td><td rowspan="1" colspan="1">1193</td><td rowspan="1" colspan="1">gyrA_S83L gyrA_D87N<break/>parC_S80I<break/>parE_L416F</td><td rowspan="1" colspan="1">qepA8<sup><xref rid="dkac402-tblfn11" ref-type="table-fn">b</xref></sup></td><td rowspan="1" colspan="1">marR_S3N</td><td rowspan="1" colspan="1">CTX-M-15, CMY-2</td></tr></tbody></table><table-wrap-foot><fn id="dkac402-tblfn9"><p>Ciprofloxacin MIC testing in CAMHB and mSHU was performed in triplicate by BMD using ciprofloxacin HCl (Sigma&#8211;Aldrich USA, PHR1044); median (range) reported. Testing in pooled human urine was performed as a single replicate using the parental formulation of ciprofloxacin (Aspen Pharmacare Australia). Testing performed in CAMHB and mSHU. QRDRs include mutations DNA gyrase (<italic toggle="yes">gyr</italic>) and topoisomerase IV (<italic toggle="yes">par</italic>) genes.</p></fn><fn id="dkac402-tblfn10"><p>Partial genomic sequence obtained (104/657 bases missing from assembly).</p></fn><fn id="dkac402-tblfn11"><p>Partial genomic sequence obtained (286/1542 bases missing from assembly). The ATCC 25922 strain matched the publicly available sequence.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dkac402-s2.2"><title>Simulated ciprofloxacin exposure in the bladder infection model</title><p>Ciprofloxacin concentrations closely matched target values with the linear regression slope 0.90 (R<sup>2&#8202;</sup>=&#8202;0.9758) and bias &#8722;1.9% (95% CI: &#8722;35.2% to 31.5%) (Figures <xref rid="sup1" ref-type="supplementary-material">S2 and S3</xref>). Intercompartment variation in <italic toggle="yes">C</italic><sub>max</sub> across all 16 bladders on the third day treatment was 3.3%&#8202;&#177;&#8202;0.8%. Interday variation in <italic toggle="yes">C</italic><sub>max</sub> in the representative sampled bladders was 7.6%&#8202;&#177;&#8202;5.9%. All ciprofloxacin concentrations measured at follow-up (96 h) were &lt;0.27 mg/L.</p></sec><sec id="dkac402-s2.3"><title>Post-exposure growth response in the bladder infection model</title><p>
<italic toggle="yes">E. coli</italic> ATCC 25922 (ciprofloxacin MIC 0.008 mg/L) was eradicated in all dosing regimens. The six clinical isolates with ciprofloxacin MIC&#8202;&#8805;&#8202;16 mg/L had near maximal regrowth at 72 h (&gt;1.9 &#916;log<sub>10</sub> cfu/mL) in all dosing regimens (Table <xref rid="dkac402-T3" ref-type="table">3</xref> and Figure <xref rid="dkac402-F3" ref-type="fig">3</xref>). For the remaining nine clinical isolates (ciprofloxacin MIC 0.25&#8211;8 mg/L), after an initial period of killing, regrowth at 72 h (&gt;0 &#916;log<sub>10</sub> cfu/mL) was: three isolates (114, 132, 104 with MICs 4&#8211;8 mg/L) after 250 mg and 500 mg daily; one isolate (104 with MIC 8 mg/L) after 250 mg and 500 mg 12 hourly; none after 750 mg 12 hourly. At follow-up (96 h) regrowth in these nine isolates was: seven isolates (057, 017, 016, 019, 114, 132, 104 with MICs 0.5&#8211;8 mg/L) after 250 mg daily; five isolates (014, 016, 114, 132, 104 with MICs 0.5&#8211;8 mg/L) after 500 mg daily; three isolates (114, 132, 104) after 250 mg and 500 mg 12 hourly; one isolate (114 with MIC 4 mg/L) after 750 mg 12 hourly.</p><fig position="float" id="dkac402-F3" fig-type="figure" orientation="portrait"><label>Figure 3.</label><caption><p>Growth response following urinary ciprofloxacin exposure over 96 h incubation in the bladder infection model following the five dosing regimens (a&#8211;e). Sixteen <italic toggle="yes">E. coli</italic> isolates tested, each with a unique symbol. Limit of detection was considered to be 50 cfu/mL. Circled times on the <italic toggle="yes">x</italic>-axis indicate the time when repeat doses of ciprofloxacin were added to the <italic toggle="yes">in vitro</italic> model. This figure appears in colour in the online version of <italic toggle="yes">JAC</italic> and in black and white in the print version of <italic toggle="yes">JAC</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dkac402f3.jpg"/></fig><table-wrap position="float" id="dkac402-T3" orientation="portrait"><label>Table 3.</label><caption><p>Change in bacterial density at 72 and 96 h following oral ciprofloxacin dosing simulations</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Isolate #</th><th align="center" rowspan="2" colspan="1">CIP MIC (mg/L)</th><th align="center" colspan="5" rowspan="1">End of treatment (72 h &#916;cfu/mL)</th><th align="center" colspan="5" rowspan="1">Follow-up (96 h &#916;cfu/mL)</th></tr><tr><th align="center" rowspan="1" colspan="1">250 mg daily</th><th align="center" rowspan="1" colspan="1">500 mg daily</th><th align="center" rowspan="1" colspan="1">250 mg q12</th><th align="center" rowspan="1" colspan="1">500 mg q12</th><th align="center" rowspan="1" colspan="1">750 mg q12</th><th align="center" rowspan="1" colspan="1">250 mg daily</th><th align="center" rowspan="1" colspan="1">500 mg daily</th><th align="center" rowspan="1" colspan="1">250 mg q12</th><th align="center" rowspan="1" colspan="1">500 mg q12</th><th align="center" rowspan="1" colspan="1">750 mg q12</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">25922</td><td rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">057</td><td rowspan="1" colspan="1">0.25</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">1.35</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8722;1.52</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">017</td><td rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">1.74</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">014</td><td rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8722;0.43</td><td rowspan="1" colspan="1">1.17</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">015</td><td rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">016</td><td rowspan="1" colspan="1">0.5</td><td rowspan="1" colspan="1">&#8722;0.46</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">1.96</td><td rowspan="1" colspan="1">1.08</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">019</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">&#8722;2.83</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">1.57</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">&#8722;3.29</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">114</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">2.27</td><td rowspan="1" colspan="1">0.86</td><td rowspan="1" colspan="1">&#8722;0.68</td><td rowspan="1" colspan="1">&#8722;0.50</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">2.18</td><td rowspan="1" colspan="1">1.79</td><td rowspan="1" colspan="1">1.82</td><td rowspan="1" colspan="1">1.94</td><td rowspan="1" colspan="1">1.26</td></tr><tr><td rowspan="1" colspan="1">132</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">1.92</td><td rowspan="1" colspan="1">1.47</td><td rowspan="1" colspan="1">&#8722;3.69</td><td rowspan="1" colspan="1">&#8722;0.48</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">2.00</td><td rowspan="1" colspan="1">1.69</td><td rowspan="1" colspan="1">1.44</td><td rowspan="1" colspan="1">2.12</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">104</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">2.19</td><td rowspan="1" colspan="1">2.05</td><td rowspan="1" colspan="1">0.41</td><td rowspan="1" colspan="1">1.51</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td rowspan="1" colspan="1">2.13</td><td rowspan="1" colspan="1">1.87</td><td rowspan="1" colspan="1">1.82</td><td rowspan="1" colspan="1">2.04</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td rowspan="1" colspan="1">093</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">2.08</td><td rowspan="1" colspan="1">2.23</td><td rowspan="1" colspan="1">2.48</td><td rowspan="1" colspan="1">2.95</td><td rowspan="1" colspan="1">2.51</td><td rowspan="1" colspan="1">1.98</td><td rowspan="1" colspan="1">2.27</td><td rowspan="1" colspan="1">2.12</td><td rowspan="1" colspan="1">2.44</td><td rowspan="1" colspan="1">2.25</td></tr><tr><td rowspan="1" colspan="1">124</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">3.17</td><td rowspan="1" colspan="1">2.20</td><td rowspan="1" colspan="1">2.68</td><td rowspan="1" colspan="1">3.02</td><td rowspan="1" colspan="1">1.98</td><td rowspan="1" colspan="1">2.65</td><td rowspan="1" colspan="1">2.06</td><td rowspan="1" colspan="1">2.28</td><td rowspan="1" colspan="1">3.11</td><td rowspan="1" colspan="1">1.98</td></tr><tr><td rowspan="1" colspan="1">096</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">2.57</td><td rowspan="1" colspan="1">2.21</td><td rowspan="1" colspan="1">2.64</td><td rowspan="1" colspan="1">3.81</td><td rowspan="1" colspan="1">2.56</td><td rowspan="1" colspan="1">2.82</td><td rowspan="1" colspan="1">1.81</td><td rowspan="1" colspan="1">1.43</td><td rowspan="1" colspan="1">2.74</td><td rowspan="1" colspan="1">2.15</td></tr><tr><td rowspan="1" colspan="1">127</td><td rowspan="1" colspan="1">64</td><td rowspan="1" colspan="1">1.89</td><td rowspan="1" colspan="1">1.96</td><td rowspan="1" colspan="1">2.29</td><td rowspan="1" colspan="1">2.10</td><td rowspan="1" colspan="1">2.10</td><td rowspan="1" colspan="1">2.23</td><td rowspan="1" colspan="1">1.80</td><td rowspan="1" colspan="1">1.94</td><td rowspan="1" colspan="1">2.00</td><td rowspan="1" colspan="1">2.22</td></tr><tr><td rowspan="1" colspan="1">139</td><td rowspan="1" colspan="1">128</td><td rowspan="1" colspan="1">2.09</td><td rowspan="1" colspan="1">1.94</td><td rowspan="1" colspan="1">2.74</td><td rowspan="1" colspan="1">3.03</td><td rowspan="1" colspan="1">1.98</td><td rowspan="1" colspan="1">2.00</td><td rowspan="1" colspan="1">1.96</td><td rowspan="1" colspan="1">1.74</td><td rowspan="1" colspan="1">2.26</td><td rowspan="1" colspan="1">2.18</td></tr><tr><td rowspan="1" colspan="1">087</td><td rowspan="1" colspan="1">512</td><td rowspan="1" colspan="1">1.96</td><td rowspan="1" colspan="1">1.77</td><td rowspan="1" colspan="1">2.51</td><td rowspan="1" colspan="1">2.14</td><td rowspan="1" colspan="1">2.10</td><td rowspan="1" colspan="1">1.91</td><td rowspan="1" colspan="1">1.88</td><td rowspan="1" colspan="1">1.81</td><td rowspan="1" colspan="1">2.01</td><td rowspan="1" colspan="1">2.18</td></tr></tbody></table><table-wrap-foot><fn id="dkac402-tblfn12"><p>CIP, ciprofloxacin. CIP MIC as determined by BMD in CAMHB. &#8212; indicates that growth was not detected. Limit of detection was considered to be 50 cfu/mL.</p></fn></table-wrap-foot></table-wrap></sec><sec id="dkac402-s2.4"><title>Emergence of resistance</title><p>Ciprofloxacin MIC testing of post-exposure growth from drug-free MHA did not identify any isolate with &gt;2 log<sub>2</sub> dilution rise MIC compared with the starting inoculum (Table <xref rid="sup1" ref-type="supplementary-material">S3</xref>). Only isolate 019 (MIC 0.5 to 2 mg/L after 250 mg 12 hourly) and isolate 127 (MIC 32 to 128 mg/L after 750 mg 12 hourly) had appreciable MIC rises. Emergence of resistance was also not detected on the bacterial density measurements on MHA supplemented with 2 and 128 mg/L ciprofloxacin. MHA with 2 mg/L ciprofloxacin suppressed all isolates with ciprofloxacin MIC&#8202;&lt;&#8202;2 mg/L. MHA with 128 mg/L ciprofloxacin suppressed all isolates with ciprofloxacin MIC 2&#8211;64 mg/L, except 127 (ciprofloxacin MIC 64 mg/L), which had low-level growth at 96 h (2&#8211;3 log<sub>10</sub> cfu/mL) following 250 mg daily, 250 mg 12 hourly and 500 mg 12 hourly, with a ciprofloxacin MIC of 128&#8211;256 mg/L.</p></sec><sec id="dkac402-s2.5"><title>PK/PD analysis</title><p>The <italic toggle="yes">E</italic><sub>max</sub> model well described the PK/PD relationship for the primary endpoint (&#916;log<sub>10</sub> cfu/mL at 72 h) with AUC<sub>0&#8211;24</sub>/MIC EI<sub>50</sub>&#8202;=&#8202;887 (R<sup>2</sup> 0.9062) and <italic toggle="yes">C</italic><sub>max</sub>/MIC EI<sub>50</sub>&#8202;=&#8202;76 (R<sup>2</sup> 0.8766) (Figure <xref rid="dkac402-F4" ref-type="fig">4</xref>). Target PK/PD ranged from 684 AUC<sub>0&#8211;24</sub>/MIC and 56 C<sub>max</sub>/MIC for stasis to 1521 AUC<sub>0&#8211;24</sub>/MIC and 147 <italic toggle="yes">C</italic><sub>max</sub>/MIC for 3 log<sub>10</sub> kill (Table <xref rid="dkac402-T4" ref-type="table">4</xref>). The PK/PD relationships for the secondary endpoints (&#916;log<sub>10</sub> cfu/mL at 96 h, and AUBKC<sub>0&#8211;96</sub>) are presented in Table <xref rid="dkac402-T3" ref-type="table">3</xref>. The best goodness of fit for data was generated using the AUBKC<sub>0&#8211;96</sub> endpoint, with an AUC<sub>0&#8211;24</sub>/MIC EI<sub>50</sub>&#8202;=&#8202;692 (R<sup>2</sup> 0.9307) and <italic toggle="yes">C</italic><sub>max</sub>/MIC EI<sub>50</sub>&#8202;=&#8202;57 (R<sup>2</sup> 0.9082). With MIC values measured by BMD in mSHU, the AUC<sub>0&#8211;24</sub>/MIC<sub>mSHU</sub> targets for &#916;log<sub>10</sub> cfu/mL at 72 h ranged from 27 for stasis to 72 for 3 log<sub>10</sub> kill. Similarly, the total bacterial response (AUBKC<sub>0&#8211;96</sub>) had the best goodness of fit (R<sup>2</sup> 0.9207), with the AUC<sub>0&#8211;24</sub>/MIC<sub>mSHU</sub> EI<sub>50</sub>&#8202;=&#8202;30, and EI<sub>90</sub>&#8202;=&#8202;100 (Table <xref rid="sup1" ref-type="supplementary-material">S4</xref> and Figure <xref rid="sup1" ref-type="supplementary-material">S4</xref>).</p><fig position="float" id="dkac402-F4" fig-type="figure" orientation="portrait"><label>Figure 4.</label><caption><p>Exposure&#8211;response relationships. <italic toggle="yes">E</italic><sub>max</sub> models detailing the relationship between exposure [AUC<sub>0&#8211;24</sub>/MIC (left) and <italic toggle="yes">C</italic><sub>max</sub>/MIC (right)] and the change in bacterial density, measured at (a) 72 h and (b) 96 h, and the total bacterial response (c) AUBKC<sub>0&#8211;96</sub>. This figure appears in colour in the online version of <italic toggle="yes">JAC</italic> and in black and white in the print version of <italic toggle="yes">JAC</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dkac402f4.jpg"/></fig><table-wrap position="float" id="dkac402-T4" orientation="portrait"><label>Table 4.</label><caption><p>Ciprofloxacin urinary PK/PD targets for different bacterial response endpoints</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col valign="top" align="left" span="1"/><col valign="top" align="center" span="1"/><col valign="top" align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">AUC<sub>0&#8211;24</sub>/MIC (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub>/MIC (95% CI)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">End of treatment: 72 h &#916;log<sub>10</sub> cfu/mL</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>Stasis</td><td rowspan="1" colspan="1">684 (557&#8211;821)</td><td rowspan="1" colspan="1">56 (45&#8211;71)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>1 log<sub>10</sub> kill</td><td rowspan="1" colspan="1">878 (730&#8211;1063)</td><td rowspan="1" colspan="1">76 (62&#8211;100)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>2 log<sub>10</sub> kill</td><td rowspan="1" colspan="1">1125 (933&#8211;1420)</td><td rowspan="1" colspan="1">102 (80&#8211;145)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>3 log<sub>10</sub> kill</td><td rowspan="1" colspan="1">1521 (1185&#8211;2025)</td><td rowspan="1" colspan="1">147 (104&#8211;222)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>R<sup>2</sup></td><td rowspan="1" colspan="1">0.9062</td><td rowspan="1" colspan="1">0.8766</td></tr><tr><td colspan="3" rowspan="1">Follow-up: 96 h &#916;log<sub>10</sub> cfu/mL</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>Stasis</td><td rowspan="1" colspan="1">1534 (949&#8211;2225)</td><td rowspan="1" colspan="1">123 (69&#8211;199)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>1 log<sub>10</sub> kill</td><td rowspan="1" colspan="1">2383 (1607&#8211;3306)</td><td rowspan="1" colspan="1">204 (123&#8211;313)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>2 log<sub>10</sub> kill</td><td rowspan="1" colspan="1">3651 (2584&#8211;5207)</td><td rowspan="1" colspan="1">338 (211&#8211;524)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>3 log<sub>10</sub> kill</td><td rowspan="1" colspan="1">6045 (4078&#8211;9602)</td><td rowspan="1" colspan="1">633 (374&#8211;1274)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>R<sup>2</sup></td><td rowspan="1" colspan="1">0.7504</td><td rowspan="1" colspan="1">0.6927</td></tr><tr><td colspan="3" rowspan="1">Total bacterial response: AUBKC<sub>0&#8211;96</sub></td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>EI<sub>50</sub></td><td rowspan="1" colspan="1">692 (562&#8211;861)</td><td rowspan="1" colspan="1">57 (45&#8211;76)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>EI<sub>90</sub></td><td rowspan="1" colspan="1">2727 (1778&#8211;4599)</td><td rowspan="1" colspan="1">253 (146&#8211;527)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#515;</italic>R<sup>2</sup></td><td rowspan="1" colspan="1">0.9307</td><td rowspan="1" colspan="1">0.9082</td></tr></tbody></table><table-wrap-foot><fn id="dkac402-tblfn13"><p>Non-linear regression <italic toggle="yes">E</italic><sub>max</sub> curves described by the equation: E&#8202;=&#8202;(<italic toggle="yes">E</italic><sub>max</sub>&#8202;&#8722;&#8202;<italic toggle="yes">E</italic><sub>min</sub>)&#8202;&#215;&#8202;EI<sup>n</sup>/(EI<sup>n</sup>&#8202;+&#8202;EI<sup>n</sup><sub>50</sub>)&#8202;+&#8202;<italic toggle="yes">E</italic><sub>min</sub>, where <italic toggle="yes">E</italic><sub>max</sub> reflects maximal growth and <italic toggle="yes">E</italic><sub>min</sub> reflects no growth, EI is the exposure index of AUC<sub>0&#8211;24</sub>/MIC and <italic toggle="yes">C</italic><sub>max</sub>/MIC, EI<sub>50</sub> is the exposure index required to achieve 50% of <italic toggle="yes">E</italic><sub>max</sub>, EI<sub>90</sub> is the exposure index required to achieve 90% of <italic toggle="yes">E</italic><sub>max</sub>, and n is the slope of the dose&#8211;effect relationship (Hill coefficient).</p></fn></table-wrap-foot></table-wrap></sec><sec id="dkac402-s2.6"><title>Monte Carlo simulation</title><p>PTA applying AUC<sub>0&#8211;24</sub>/MIC targets for the primary endpoint (72 h &#916;log<sub>10</sub> cfu/mL) for each oral ciprofloxacin dosing regimen is graphed overlying <italic toggle="yes">E. coli</italic> ciprofloxacin MIC distributions (Figure <xref rid="dkac402-F5" ref-type="fig">5</xref>). A &gt;95% PTA for a 3 log<sub>10</sub> kill effect following 250 mg daily, 500 mg daily, 250 mg 12 hourly, 500 mg 12 hourly and 750 mg 12 hourly was found for isolates with ciprofloxacin MICs of &#8804;0.25, 0.5, 0.5, 1 and 1 mg/L. A &gt;95% PTA for stasis was found for isolates with ciprofloxacin MICs of &#8202;&#8804;&#8202;0.5, 1, 1, 2 and 4 mg/L for each dosing regimen, respectively (Table <xref rid="sup1" ref-type="supplementary-material">S5</xref>).</p><fig position="float" id="dkac402-F5" fig-type="figure" orientation="portrait"><label>Figure 5.</label><caption><p>End-of-treatment (72 h) Monte Carlo simulation. PTA of stasis and log kill at 72 h for 12 hourly dosing of oral ciprofloxacin at (a) 250, (b) 500, and (c) 750 mg. Graphs overlying the ciprofloxacin MIC distribution from the 93 ceftriaxone-resistant <italic toggle="yes">E. coli</italic> clinical isolates (top row) and the EUCAST MIC distribution (bottom row). PTA values are shown in Table <xref rid="sup1" ref-type="supplementary-material">S3</xref>. This figure appears in colour in the online version of <italic toggle="yes">JAC</italic> and in black and white in the print version of <italic toggle="yes">JAC</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dkac402f5.jpg"/></fig><p>Secondary endpoints [follow-up (96 h); total bacterial response (AUBKC<sub>0&#8211;96</sub>)] are presented in Tables <xref rid="sup1" ref-type="supplementary-material">S6 and S7</xref> and Figures <xref rid="sup1" ref-type="supplementary-material">S5 and S6</xref>. A ciprofloxacin MIC&#8202;&#8804;&#8202;1 mg/L allowed for &gt;95% PTA for a 1 log<sub>10</sub> kill at follow-up (96 h) and 90% maximal efficacy with high (750 mg 12 hourly) dosing. For standard dosing (500 mg 12 hourly) and low dosing (250 mg 12 hourly), PK/PD breakpoints are MIC&#8202;&#8804;&#8202;0.5 and&#8202;&#8804;&#8202;0.25 mg/L for 1 log<sub>10</sub> kill at 96 h, and MIC&#8202;&#8804;&#8202;0.5 and&#8202;&#8804;&#8202;0.25 mg/L for 90% maximal efficacy for AUBKC<sub>0&#8211;96</sub>.</p></sec></sec><sec sec-type="discussion" id="dkac402-s3"><title>Discussion</title><p>PK/PD analysis and MCS support the <italic toggle="yes">in vitro</italic> efficacy of high-dose ciprofloxacin (750 mg orally 12 hourly) against <italic toggle="yes">E. coli</italic> urinary isolates with a ciprofloxacin MIC&#8202;&#8804;&#8202;1 mg/L for a 3 log<sub>10</sub> kill at the end of 3 days of treatment, 1 log<sub>10</sub> kill at follow-up (at 96 h), and 90% maximal activity (AUBKC<sub>0&#8211;96</sub>). Standard-dose ciprofloxacin (500 mg 12 hourly) similarly achieved 3 log<sub>10</sub> kill at 72 h at MIC&#8202;&#8804;&#8202;1 mg/L, whereas 1 log<sub>10</sub> kill at 96 h and 90% maximal activity required a lower MIC of &#8804;0.5 mg/L. Low-dose ciprofloxacin (250 mg 12 hourly, or 500 mg daily) achieved 3 log<sub>10</sub> kill at 72 h at MIC&#8202;&#8804;&#8202;0.5 mg/L, 1 log<sub>10</sub> kill at 96 h and 90% maximal activity at MIC&#8202;&#8804;&#8202;0.25 mg/L. These data support current ciprofloxacin dosing practices for UTIs caused by <italic toggle="yes">E. coli</italic> categorized as susceptible (MIC&#8202;&#8804;&#8202;0.25 mg/L), and the potential to expand activity with high-dose therapy for urinary isolates with low-level ciprofloxacin resistance (MIC&#8202;&#8804;&#8202;1 mg/L).</p><p>Expanding ciprofloxacin susceptibility can provide an oral antimicrobial option for select groups of patients, such as: UTIs caused by MDR bacteria; oral step-down following initial IV therapy; infections following urinary tract instrumentation; infections in males; catheter-associated UTIs; and after consultation with clinical colleagues. However, given restrictions on the use of ciprofloxacin by the EMA and FDA, any change to ciprofloxacin breakpoints would need to ensure that ciprofloxacin is not promoted for uncomplicated and recurrent UTIs. Using cascade (or selective) reporting provides a valuable antimicrobial stewardship strategy for the reporting laboratory.<sup><xref rid="dkac402-B35" ref-type="bibr">35</xref>,<xref rid="dkac402-B36" ref-type="bibr">36</xref></sup></p><p>Established ciprofloxacin target plasma PK/PD ratios are <italic toggle="yes">f</italic>AUC/MIC ratio of 140 for 2 log<sub>10</sub> kill in a neutropenic thigh model and <italic toggle="yes">f</italic>AUC/MIC ratio of 87.5 for clinical efficacy in hospital-acquired pneumonia.<sup><xref rid="dkac402-B37" ref-type="bibr">37</xref></sup> Despite PK data recording high ciprofloxacin concentrations in urine, neither animal nor clinical PK/PD targets exist for UTIs. The UTI PK/PD targets determined in the present study were 8&#8211;16 times higher than plasma targets. This reflects a reduction in the activity of ciprofloxacin in a bladder infection model and supported by elevated MIC measurements in mSHU and pooled human urine (three to four 2-fold increase compared with testing in CAMHB). When applying ciprofloxacin MIC values measured by BMD in mSHU, the resulting urinary PK/PD targets are similar to the plasma targets in the literature. Namely, <italic toggle="yes">f</italic>AUC/MIC<sub>mSHU</sub> ratio of 72 for 3 log<sub>10</sub> kill at 72 h, <italic toggle="yes">f</italic>AUC/MIC<sub>mSHU</sub> ratio of 149 for 1 log<sub>10</sub> kill at 96 h, and <italic toggle="yes">f</italic>AUC/MIC<sub>mSHU</sub> ratio of 100 for 90% maximal activity (AUBKC<sub>0&#8211;96</sub>). These observations support the clinical correlation of the bladder infection model to predict antibiotic efficacy in UTIs. However, applying non-standardized MIC measurements limits the practical translation of the <italic toggle="yes">in vitro</italic> results. The MIC should be measured by the reference method to provide a phenotypic endpoint in a defined and standardized system as a reproducible measure of antibiotic activity against that microorganism. The value should not be extrapolated as a concentration directly comparable with <italic toggle="yes">in vivo</italic> concentrations found at the site of infection during treatment.<sup><xref rid="dkac402-B38" ref-type="bibr">38</xref></sup></p><p>Establishing UTI-specific PK/PD targets can inform optimized antibiotic dosing strategies. However, simulating urinary PK has greater complexity compared with plasma PK given the marked variability observed between individuals, largely due to fluid intake and voiding behaviour (Table <xref rid="dkac402-T1" ref-type="table">1</xref>). Antibiotic protein binding, which is an important consideration in plasma PK, is less of an issue when considering free-drug activity and total drug measurements in urine, given the renal excretion of unbound drug and the paucity of albumin found in urine in patients with normal renal glomerular function.<sup><xref rid="dkac402-B39" ref-type="bibr">39</xref>,<xref rid="dkac402-B40" ref-type="bibr">40</xref></sup> Urinary ciprofloxacin PK variability has been modelled in relation to urine output (1 versus 2.5 L/day), healthy young adults versus elderly, and circadian changes in diuresis and absorption.<sup><xref rid="dkac402-B41" ref-type="bibr">41</xref></sup> Such variability in urinary PK is not unique to ciprofloxacin. Wijma <italic toggle="yes">et al.</italic><sup><xref rid="dkac402-B42" ref-type="bibr">42</xref></sup> found a 47% coefficient of variability (CV%) in urinary fosfomycin exposure (AUC<sub>0&#8211;48</sub> 21284&#8202;&#177;&#8202;9965 mg&#183;h/L). Similarly, Wenzler <italic toggle="yes">et al.</italic><sup><xref rid="dkac402-B43" ref-type="bibr">43</xref></sup> measured urinary fosfomycin concentrations at selected time periods with a CV% of 67%&#8211;84%, and a similar CV% in the volume of urine voided (60%&#8211;73%). Informed from these studies, and those presented in Table <xref rid="dkac402-T1" ref-type="table">1</xref>, we applied a &#177;50% variability in the expected urinary ciprofloxacin exposure (AUC<sub>0&#8211;24</sub>) in our MCS.</p><p>Mutations associated with low- and high-level ciprofloxacin resistance are complex and varied.<sup><xref rid="dkac402-B44" ref-type="bibr">44</xref></sup> In our 15 clinical <italic toggle="yes">E. coli</italic> isolates, ciprofloxacin MIC appeared to be related to the type and number of mutations detected. This has been similarly reported in <italic toggle="yes">qnr</italic>-containing <italic toggle="yes">E. coli</italic> with additional topoisomerase mutations and increased expression of efflux pump genes.<sup><xref rid="dkac402-B45" ref-type="bibr">45</xref></sup> Subinhibitory antibiotic concentrations have also been reported to promote resistance via target mutations and changes in drug efflux.<sup><xref rid="dkac402-B46" ref-type="bibr">46</xref></sup> An interesting observation from our data is the overall lack of emergence of ciprofloxacin resistance, determined by MIC testing at follow-up (96 h) and plating on MHA supplemented with 2 and 128 mg/L ciprofloxacin. We did not repeat WGS on the post-exposure growth or assess efflux expression. Possible explanations could be the down-regulation of genes prior to MIC testing, or that regrowth reflects tolerance, persistence and quiescence.<sup><xref rid="dkac402-B47" ref-type="bibr">47</xref>,<xref rid="dkac402-B48" ref-type="bibr">48</xref></sup></p><p>First-line oral antimicrobials, nitrofurantoin and fosfomycin, may not be preferred agents for a variety of clinical reasons. Their activity beyond the bladder is uncertain, renal impairment impacts on nitrofurantoin,<sup><xref rid="dkac402-B49" ref-type="bibr">49</xref></sup> and fosfomycin is not reliably active against non-<italic toggle="yes">E. coli</italic> uropathogens.<sup><xref rid="dkac402-B50" ref-type="bibr">50</xref></sup> Alternatively, amoxicillin/clavulanate for the treatment of ESBL-producing uropathogens has been supported by several observational studies.<sup><xref rid="dkac402-B51" ref-type="bibr">51</xref>,<xref rid="dkac402-B52" ref-type="bibr">52</xref></sup> However, a randomized control trial comparing 3 days of amoxicillin/clavulanate with 3 days of ciprofloxacin demonstrated a higher failure rate with amoxicillin/clavulanate.<sup><xref rid="dkac402-B53" ref-type="bibr">53</xref></sup> The potential superiority of fluoroquinolones over other agents, including &#946;-lactams, has been reported in two systematic reviews.<sup><xref rid="dkac402-B54" ref-type="bibr">54</xref>,<xref rid="dkac402-B55" ref-type="bibr">55</xref></sup></p><p>New oral antimicrobials for ESBL-producing uropathogens include: third-generation oral cephalosporins with clavulanate;<sup><xref rid="dkac402-B56" ref-type="bibr">56</xref></sup> oral carbapenems (sulopenem non-inferior to ciprofloxacin,<sup><xref rid="dkac402-B57" ref-type="bibr">57</xref></sup> tebipenem non-inferior to ertapenem<sup><xref rid="dkac402-B58" ref-type="bibr">58</xref>,<xref rid="dkac402-B59" ref-type="bibr">59</xref></sup>); omadacycline;<sup><xref rid="dkac402-B60" ref-type="bibr">60</xref></sup> gepotidacin;<sup><xref rid="dkac402-B61" ref-type="bibr">61</xref></sup> and oral &#946;-lactamase inhibitors (QPX7728, ETX0282, VNRX7145 and ARX1796).<sup><xref rid="dkac402-B62" ref-type="bibr">62&#8211;64</xref></sup> Although these agents may provide valuable future options, the complexities of licensing new agents can limit their availability, as evidenced by an FDA regulatory hurdle for tebipenem that prompted Spero Therapeutics to suspend commercialization activities.</p><p>Our dynamic <italic toggle="yes">in vitro</italic> model applies a high media flow rate and large volume shifts that mimic urodynamics and mSHU to reflect the urinary environment. The addition of yeast extract and casamino acids to the 18 chemical components included in the mSHU enables the <italic toggle="yes">E. coli</italic> uropathogens to have a similar growth rate to growth in human urine, while not expected to bind free ciprofloxacin. However, the bactericidal activity of the ciprofloxacin is decreased by several <italic toggle="yes">in vivo</italic> conditions, including the presence of cations and acidic urine pH leading to higher MICs.<sup><xref rid="dkac402-B65" ref-type="bibr">65</xref>,<xref rid="dkac402-B66" ref-type="bibr">66</xref></sup> Other dynamic PK/PD <italic toggle="yes">in vitro</italic> models studying ciprofloxacin against <italic toggle="yes">E. coli</italic> have either lacked urodynamic simulation,<sup><xref rid="dkac402-B67" ref-type="bibr">67</xref></sup> or were not specific for UTIs (i.e. urinary ciprofloxacin exposures; media mimicking urine).<sup><xref rid="dkac402-B68" ref-type="bibr">68</xref>,<xref rid="dkac402-B69" ref-type="bibr">69</xref></sup> Where urodynamics and the urinary environment were simulated, as performed using the original UTI bladder infection <italic toggle="yes">in vitro</italic> model,<sup><xref rid="dkac402-B70" ref-type="bibr">70</xref></sup> and a dilutional model,<sup><xref rid="dkac402-B71" ref-type="bibr">71</xref></sup> fluoroquinolones were very effective against <italic toggle="yes">E. coli</italic> isolates.</p><p>Compared with <italic toggle="yes">in vivo</italic> studies, a mouse ascending UTI model demonstrated that isogenic <italic toggle="yes">E. coli</italic> strains with low-level ciprofloxacin resistance genes (<italic toggle="yes">qnrA1</italic>, MIC 0.19 mg/L; <italic toggle="yes">qnrB19</italic>, MIC 0.38 mg/L; <italic toggle="yes">qnrS1</italic>, MIC 0.38 mg/L) had reduced ciprofloxacin kill in urine and bladder bacterial counts compared with the WT strain (MIC 0.032 mg/L), despite ciprofloxacin reaching high urine concentrations (urinary AUC<sub>0&#8211;24</sub> 2572 mg&#183;h/L, urinary <italic toggle="yes">C</italic><sub>max</sub> 553 mg/L) following the dose of 0.2 mg per mouse four times daily to correspond to a human dose of 500 mg twice daily.<sup><xref rid="dkac402-B72" ref-type="bibr">72</xref></sup> In another mouse model of ascending UTI in diabetic mice, following ciprofloxacin dose-fraction studies a plasma exposure&#8211;response relationship was found with an approximate AUC/MIC IC<sub>50</sub> of 120&#8211;170.<sup><xref rid="dkac402-B73" ref-type="bibr">73</xref></sup> A 24 h plasma AUC/MIC of &#8764;400 associated with complete bacterial clearance in kidneys and bladder tissues.<sup><xref rid="dkac402-B73" ref-type="bibr">73</xref></sup> Corresponding to human exposures following oral 500 mg 12 hourly, a mouse equivalent dose (196 mg/L) would be expected to provide exposures correlating with significant microbiology activity in bladder, kidney and urine and resolution of clinical symptoms (plasma AUC/MIC of 566). As urine ciprofloxacin concentrations were not measured, plasma concentrations were considered as a surrogate to evaluate therapeutic concentrations in the bladder and kidneys. This study was limited by infecting mice with the fully ciprofloxacin susceptible <italic toggle="yes">E. coli</italic> ATCC 25922 strain and assessing the response over 24 h.</p><p>There are important limitations to our <italic toggle="yes">in vitro</italic> model, including the lack of host response and bladder tissue architecture. Immunocompetent and novel &#8216;bladder-on-a-chip&#8217; <italic toggle="yes">in vitro</italic> models have attempted to overcome some of these limitations.<sup><xref rid="dkac402-B74" ref-type="bibr">74</xref>,<xref rid="dkac402-B75" ref-type="bibr">75</xref></sup> Our findings are also specific to <italic toggle="yes">E. coli</italic> and may not directly translate to other uropathogens. Furthermore, it is uncertain if these data can be extrapolated to complicated UTI, or patients with renal dysfunction. This work does not examine extended-release formulations of oral ciprofloxacin that have comparable clinical outcomes,<sup><xref rid="dkac402-B76" ref-type="bibr">76&#8211;78</xref></sup> with the benefit of daily administration, high urinary drug levels over the entire 24 h period, higher peak plasma concentrations, superior bactericidal activity and lower interpatient variability.<sup><xref rid="dkac402-B79" ref-type="bibr">79</xref></sup></p><p>In summary, these data support oral ciprofloxacin efficacy for <italic toggle="yes">E. coli</italic> urinary isolates with MIC&#8202;&#8804;&#8202;0.25 mg/L with the standard dose and with MIC&#8202;&#8804;&#8202;1 mg/L when dosed at 750 mg 12 hourly and applying conservative measures for bacterial response. The application of urinary-specific ciprofloxacin breakpoints should be cautiously considered in specific clinical scenarios and supported with strong antimicrobial stewardship practices.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>dkac402_Supplementary_Data</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dkac402_supplementary_data.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="ack1"><title>Acknowledgments</title><p>We thank Dr Adam Jenney, Microbiology Unit, Department of Pathology, Alfred Health, Melbourne, Australia for providing the baseline collection of <italic toggle="yes">E. coli</italic> clinical isolates.</p></ack><sec id="dkac402-s4"><title>Funding</title><p>This study was supported by internal funding. A.Y.P. is part funded through an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowships (APP1117065). J.A.R. would like to acknowledge funding from the Australian National Health and Medical Research Council for a Centre of Research Excellence (APP2007007) and an Investigator Grant (APP2009736) as well as an Advancing Queensland Clinical Fellowship.</p></sec><sec id="dkac402-s5"><title>Transparency declarations</title><p>I.J.A. has received consultancies/advisory boards for MSD. J.M. has received research grants from Pfizer, Gilead, Astellas, MSD, F2G and Venatorx. J.A.R. has consultancies/advisory boards for MSD, QPEX, Discuva Ltd, Accelerate Diagnostics, Bayer, bioM&#233;rieux; speaking fees for MSD, bioM&#233;rieux, Pfizer; industry grants from MSD, The Medicines Company, Cardeas Pharma, bioM&#233;rieux, QPEX, Pfizer. A.Y.P. has received investigator-initiated research funding from MSD. All other authors: none to declare.</p></sec><sec id="dkac402-s6"><title>Supplementary data</title><p>
<xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>, Figures <xref rid="sup1" ref-type="supplementary-material">S1 and S6</xref> and Tables <xref rid="sup1" ref-type="supplementary-material">S1 to S7</xref> are available as <xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> at <italic toggle="yes">JAC</italic> Online.</p></sec><ref-list id="ref1"><title>References</title><ref id="dkac402-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Flores-Mireles</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Walker</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Caparon</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group><article-title>Urinary tract infections: epidemiology, mechanisms of infection and treatment options</article-title>. <source>Nat Rev Microbiol</source><year>2015</year>; <volume>13</volume>: <fpage>269</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro3432</pub-id><pub-id pub-id-type="pmid">25853778</pub-id><pub-id pub-id-type="pmcid">PMC4457377</pub-id></mixed-citation></ref><ref id="dkac402-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Keijzers</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Macdonald</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Udy</surname><given-names>AA</given-names></string-name><etal>et al</etal></person-group><article-title>The Australasian resuscitation in sepsis evaluation: fluids or vasopressors in emergency department sepsis (ARISE FLUIDS), a multi-centre observational study describing current practice in Australia and New Zealand</article-title>. <source>Emerg Med Australas</source><year>2020</year>; <volume>32</volume>: <fpage>586</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1111/1742-6723.13469</pub-id><pub-id pub-id-type="pmid">32043315</pub-id><pub-id pub-id-type="pmcid">PMC7496107</pub-id></mixed-citation></ref><ref id="dkac402-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jauneikaite</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Honeyford</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Blandy</surname><given-names>O</given-names></string-name><etal>et al</etal></person-group><article-title>Bacterial genotypic and patient risk factors for adverse outcomes in <italic toggle="yes">Escherichia coli</italic> bloodstream infections: a prospective molecular epidemiological study</article-title>. <source>J Antimicrob Chemother</source><year>2022</year>; <volume>77</volume>: <fpage>1753</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkac071</pub-id><pub-id pub-id-type="pmid">35265995</pub-id><pub-id pub-id-type="pmcid">PMC9155631</pub-id></mixed-citation></ref><ref id="dkac402-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pitout</surname><given-names>JDD</given-names></string-name>, <string-name name-style="western"><surname>Peirano</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group><article-title>
<italic toggle="yes">Escherichia coli</italic> ST1193: following in the footsteps of <italic toggle="yes">E. coli</italic> ST131</article-title>. <source>Antimicrob Agents Chemother</source><year>2022</year>; <volume>66</volume>: <comment>e0051122</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.00511-22</pub-id><pub-id pub-id-type="pmcid">PMC9295538</pub-id><pub-id pub-id-type="pmid">35658504</pub-id></mixed-citation></ref><ref id="dkac402-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raja</surname><given-names>NS</given-names></string-name></person-group>. <article-title>Oral treatment options for patients with urinary tract infections caused by extended spectrum &#946;eta-lactamase (ESBL) producing Enterobacteriaceae</article-title>. <source>J Infect Public Health</source><year>2019</year>; <volume>12</volume>: <fpage>843</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2019.05.012</pub-id><pub-id pub-id-type="pmid">31176606</pub-id></mixed-citation></ref><ref id="dkac402-B6"><label>6</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>CDC</collab></person-group>. <source>Antibiotic Resistance Threats in the United States, 2019</source>. <year>2019</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf" ext-link-type="uri">https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf</ext-link>.</mixed-citation></ref><ref id="dkac402-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tutone</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bjerklund Johansen</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group><article-title>Susceptibility and resistance to fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study</article-title>. <source>Int J Antimicrob Agents</source><year>2022</year>; <volume>59</volume>: <fpage>106574</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2022.106574</pub-id><pub-id pub-id-type="pmid">35307561</pub-id></mixed-citation></ref><ref id="dkac402-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cassini</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hogberg</surname><given-names>LD</given-names></string-name>, <string-name name-style="western"><surname>Plachouras</surname><given-names>D</given-names></string-name><etal>et al</etal></person-group><article-title>Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis</article-title>. <source>Lancet Infect Dis</source><year>2019</year>; <volume>19</volume>: <fpage>56</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30605-4</pub-id><pub-id pub-id-type="pmid">30409683</pub-id><pub-id pub-id-type="pmcid">PMC6300481</pub-id></mixed-citation></ref><ref id="dkac402-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bezabih</surname><given-names>YM</given-names></string-name>, <string-name name-style="western"><surname>Sabiiti</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Alamneh</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group><article-title>The global prevalence and trend of human intestinal carriage of ESBL-producing <italic toggle="yes">Escherichia coli</italic> in the community</article-title>. <source>J Antimicrob Chemother</source><year>2021</year>; <volume>76</volume>: <fpage>22</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkaa399</pub-id><pub-id pub-id-type="pmid">33305801</pub-id></mixed-citation></ref><ref id="dkac402-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aronin</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Dunne</surname><given-names>MW</given-names></string-name><etal>et al</etal></person-group><article-title>Regional differences in antibiotic-resistant Enterobacterales urine isolates in the United States: 2018-2020</article-title>. <source>Int J Infect Dis</source><year>2022</year>; <volume>119</volume>: <fpage>142</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2022.03.052</pub-id><pub-id pub-id-type="pmid">35364285</pub-id></mixed-citation></ref><ref id="dkac402-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Antimicrobial Resistance Collaborators</collab></person-group>. <article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source>Lancet</source><year>2022</year>; <volume>399</volume>: <fpage>629</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id><pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="pmcid">PMC8841637</pub-id></mixed-citation></ref><ref id="dkac402-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zi</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group><article-title>Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019</article-title>. <source>J Clin Med</source><year>2022</year>; <volume>11</volume>: <fpage>2817</fpage>. <pub-id pub-id-type="doi">10.3390/jcm11102817</pub-id><pub-id pub-id-type="pmid">35628941</pub-id><pub-id pub-id-type="pmcid">PMC9147874</pub-id></mixed-citation></ref><ref id="dkac402-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aronoff</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Kenner</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Sloan</surname><given-names>RS</given-names></string-name><etal>et al</etal></person-group><article-title>Multiple-dose ciprofloxacin kinetics in normal subjects</article-title>. <source>Clin Pharmacol Ther</source><year>1984</year>; <volume>36</volume>: <fpage>384</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.1984.192</pub-id><pub-id pub-id-type="pmid">6467798</pub-id></mixed-citation></ref><ref id="dkac402-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gonzalez</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Uribe</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Moisen</surname><given-names>SD</given-names></string-name><etal>et al</etal></person-group><article-title>Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers</article-title>. <source>Antimicrob Agents Chemother</source><year>1984</year>; <volume>26</volume>: <fpage>741</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.26.5.741</pub-id><pub-id pub-id-type="pmid">6517556</pub-id><pub-id pub-id-type="pmcid">PMC180005</pub-id></mixed-citation></ref><ref id="dkac402-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hoffken</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lode</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Prinzing</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group><article-title>Pharmacokinetics of ciprofloxacin after oral and parenteral administration</article-title>. <source>Antimicrob Agents Chemother</source><year>1985</year>; <volume>27</volume>: <fpage>375</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.27.3.375</pub-id><pub-id pub-id-type="pmid">3158275</pub-id><pub-id pub-id-type="pmcid">PMC176280</pub-id></mixed-citation></ref><ref id="dkac402-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joos</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ledergerber</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Flepp</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group><article-title>Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine</article-title>. <source>Antimicrob Agents Chemother</source><year>1985</year>; <volume>27</volume>: <fpage>353</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.27.3.353</pub-id><pub-id pub-id-type="pmid">3158274</pub-id><pub-id pub-id-type="pmcid">PMC176276</pub-id></mixed-citation></ref><ref id="dkac402-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davis</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Koup</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Williams-Warren</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group><article-title>Pharmacokinetics of three oral formulations of ciprofloxacin</article-title>. <source>Antimicrob Agents Chemother</source><year>1985</year>; <volume>28</volume>: <fpage>74</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.28.1.74</pub-id><pub-id pub-id-type="pmid">2931047</pub-id><pub-id pub-id-type="pmcid">PMC176313</pub-id></mixed-citation></ref><ref id="dkac402-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tartaglione</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Raffalovich</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Poynor</surname><given-names>WJ</given-names></string-name><etal>et al</etal></person-group><article-title>Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses</article-title>. <source>Antimicrob Agents Chemother</source><year>1986</year>; <volume>29</volume>: <fpage>62</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.29.1.62</pub-id><pub-id pub-id-type="pmid">2942101</pub-id><pub-id pub-id-type="pmcid">PMC180365</pub-id></mixed-citation></ref><ref id="dkac402-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Catchpole</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Woodcock</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group><article-title>The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg iv and 750 mg po</article-title>. <source>J Antimicrob Chemother</source><year>1994</year>; <volume>33</volume>: <fpage>103</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/jac/33.1.103</pub-id><pub-id pub-id-type="pmid">8157550</pub-id></mixed-citation></ref><ref id="dkac402-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wagenlehner</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Wydra</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Onda</surname><given-names>H</given-names></string-name><etal>et al</etal></person-group><article-title>Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose</article-title>. <source>Antimicrob Agents Chemother</source><year>2003</year>; <volume>47</volume>: <fpage>3789</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.47.12.3789-3794.2003</pub-id><pub-id pub-id-type="pmid">14638484</pub-id><pub-id pub-id-type="pmcid">PMC296192</pub-id></mixed-citation></ref><ref id="dkac402-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Boy</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Well</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kinzig-Schippers</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group><article-title>Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose</article-title>. <source>Int J Antimicrob Agents</source><year>2004</year>; <volume>23</volume><issue>Suppl 1</issue>: <fpage>S6</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2003.09.006</pub-id><pub-id pub-id-type="pmid">15037323</pub-id></mixed-citation></ref><ref id="dkac402-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wagenlehner</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Kinzig-Schippers</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sorgel</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group><article-title>Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose</article-title>. <source>Int J Antimicrob Agents</source><year>2006</year>; <volume>28</volume>: <fpage>551</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2006.07.026</pub-id><pub-id pub-id-type="pmid">17101261</pub-id></mixed-citation></ref><ref id="dkac402-B23"><label>23</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>US FDA</collab></person-group>. <comment>Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 20 December 2018</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm" ext-link-type="uri">https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm</ext-link>.</mixed-citation></ref><ref id="dkac402-B24"><label>24</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>EMA</collab></person-group>. <comment>Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 11 March 2019</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products</ext-link>.</mixed-citation></ref><ref id="dkac402-B25"><label>25</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>EUCAST</collab></person-group>. <comment>Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, 2022</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.eucast.org" ext-link-type="uri">http://www.eucast.org</ext-link>.</mixed-citation></ref><ref id="dkac402-B26"><label>26</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>CLSI</collab></person-group>. <source>Performance Standards for Antimicrobial Susceptibility Testing&#8212;Thirty-Second Edition: M100</source>. <year>2022</year>.</mixed-citation></ref><ref id="dkac402-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abbott</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Peel</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Cairns</surname><given-names>KA</given-names></string-name><etal>et al</etal></person-group><article-title>Antibiotic management of urinary tract infections in the post-antibiotic era: a narrative review highlighting diagnostic and antimicrobial stewardship</article-title>. <source>Clin Microbiol Infect</source><year>2022</year>: <comment>S1198&#8211;743X(22)00272&#8211;5</comment>. <pub-id pub-id-type="doi">10.1016/j.cmi.2022.05.016</pub-id><pub-id pub-id-type="pmid">35640839</pub-id></mixed-citation></ref><ref id="dkac402-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stapleton</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Wagenlehner</surname><given-names>FME</given-names></string-name>, <string-name name-style="western"><surname>Mulgirigama</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group><article-title>
<italic toggle="yes">Escherichia coli</italic> resistance to fluoroquinolones in community-acquired uncomplicated urinary tract infection in women: a systematic review</article-title>. <source>Antimicrob Agents Chemother</source><year>2020</year>; <volume>64</volume>: <comment>e00862-20</comment>. <pub-id pub-id-type="doi">10.1128/AAC.00862-20</pub-id><pub-id pub-id-type="pmcid">PMC7508571</pub-id><pub-id pub-id-type="pmid">32747356</pub-id></mixed-citation></ref><ref id="dkac402-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ipe</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Ulett</surname><given-names>GC</given-names></string-name></person-group>. <article-title>Evaluation of the in vitro growth of urinary tract infection-causing gram-negative and gram-positive bacteria in a proposed synthetic human urine (SHU) medium</article-title>. <source>J Microbiol Methods</source><year>2016</year>; <volume>127</volume>: <fpage>164</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.mimet.2016.06.013</pub-id><pub-id pub-id-type="pmid">27312379</pub-id></mixed-citation></ref><ref id="dkac402-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>ISO</collab></person-group>. <comment>ISO 20776-1:2006. Clinical Laboratory Testing and In Vitro Diagnostic Test Systems - Susceptibility Testing of Infectious Agents and Evaluation of Performance of Antimicrobial Susceptibility Testing Devices- Part 1</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iso.org/standard/41630.html" ext-link-type="uri">https://www.iso.org/standard/41630.html</ext-link>.</mixed-citation></ref><ref id="dkac402-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abbott</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>van Gorp</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Wyres</surname><given-names>KL</given-names></string-name><etal>et al</etal></person-group><article-title>Oral fosfomycin activity against <italic toggle="yes">Klebsiella pneumoniae</italic> in a dynamic bladder infection <italic toggle="yes">in vitro</italic> model</article-title>. <source>J Antimicrob Chemother</source><year>2022</year>; <volume>77</volume>: <fpage>1324</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkac045</pub-id><pub-id pub-id-type="pmid">35211736</pub-id><pub-id pub-id-type="pmcid">PMC9047678</pub-id></mixed-citation></ref><ref id="dkac402-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rowe</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Morozowich</surname><given-names>W</given-names></string-name></person-group>. <article-title>A simple dilution analog computer for simulation of drug distribution processes</article-title>. <source>J Pharm Sci</source><year>1969</year>; <volume>58</volume>: <fpage>1375</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/jps.2600581117</pub-id><pub-id pub-id-type="pmid">5349753</pub-id></mixed-citation></ref><ref id="dkac402-B33"><label>33</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>FDA</collab></person-group>. <comment>Bioanalytical Method Validation: Guidance for Industry</comment>. <year>2018</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/70858/download" ext-link-type="uri">https://www.fda.gov/media/70858/download</ext-link>.</mixed-citation></ref><ref id="dkac402-B34"><label>34</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>EUCAST</collab></person-group>. <comment>EUCAST MIC distribution website</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://mic.eucast.org" ext-link-type="uri">https://mic.eucast.org</ext-link>.</mixed-citation></ref><ref id="dkac402-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kahlmeter</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Thilly</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pulcini</surname><given-names>C</given-names></string-name></person-group>. <article-title>Selective reporting of antibiotic susceptibility testing results: less is more</article-title>. <source>Clin Microbiol Infect</source><year>2021</year>; <volume>27</volume>: <fpage>503</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2020.11.017</pub-id><pub-id pub-id-type="pmid">33253937</pub-id></mixed-citation></ref><ref id="dkac402-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tebano</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Mouelhi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zanichelli</surname><given-names>V</given-names></string-name><etal>et al</etal></person-group><article-title>Selective reporting of antibiotic susceptibility testing results: a promising antibiotic stewardship tool</article-title>. <source>Expert Rev Anti Infect Ther</source><year>2020</year>; <volume>18</volume>: <fpage>251</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1080/14787210.2020.1715795</pub-id><pub-id pub-id-type="pmid">31928257</pub-id></mixed-citation></ref><ref id="dkac402-B37"><label>37</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>EUCAST</collab></person-group>. <comment>Ciprofloxacin Rationale Document, version 2.0, 2021</comment>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.eucast.org/publications_and_documents/rd/" ext-link-type="uri">https://www.eucast.org/publications_and_documents/rd/</ext-link>.</mixed-citation></ref><ref id="dkac402-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Muller</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Canton</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group><article-title>MIC-based dose adjustment: facts and fables</article-title>. <source>J Antimicrob Chemother</source><year>2018</year>; <volume>73</volume>: <fpage>564</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkx427</pub-id><pub-id pub-id-type="pmid">29216348</pub-id></mixed-citation></ref><ref id="dkac402-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ahmed</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bergmann</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zeitlinger</surname><given-names>M</given-names></string-name></person-group>. <article-title>Protein binding in translational antimicrobial development-focus on interspecies differences</article-title>. <source>Antibiotics (Basel)</source><year>2022</year>; <volume>11</volume>: <fpage>923</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics11070923</pub-id><pub-id pub-id-type="pmid">35884177</pub-id><pub-id pub-id-type="pmcid">PMC9311574</pub-id></mixed-citation></ref><ref id="dkac402-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeitlinger</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Derendorf</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></string-name><etal>et al</etal></person-group><article-title>Protein binding: do we ever learn?</article-title><source>Antimicrob Agents Chemother</source><year>2011</year>; <volume>55</volume>: <fpage>3067</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01433-10</pub-id><pub-id pub-id-type="pmid">21537013</pub-id><pub-id pub-id-type="pmcid">PMC3122431</pub-id></mixed-citation></ref><ref id="dkac402-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sanchez Navarro</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Sayalero Marinero</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Sanchez Navarro</surname><given-names>A</given-names></string-name></person-group>. <article-title>Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections</article-title>. <source>J Antimicrob Chemother</source><year>2002</year>; <volume>50</volume>: <fpage>67</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkf079</pub-id><pub-id pub-id-type="pmid">12096008</pub-id></mixed-citation></ref><ref id="dkac402-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wijma</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Koch</surname><given-names>BCP</given-names></string-name>, <string-name name-style="western"><surname>van Gelder</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group><article-title>High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers</article-title>. <source>Clin Microbiol Infect</source><year>2018</year>; <volume>24</volume>: <fpage>528</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2017.08.023</pub-id><pub-id pub-id-type="pmid">28867662</pub-id></mixed-citation></ref><ref id="dkac402-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wenzler</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ellis-Grosse</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></string-name></person-group>. <article-title>Pharmacokinetics, safety, and tolerability of single-dose intravenous (ZTI-01) and oral fosfomycin in healthy volunteers</article-title>. <source>Antimicrob Agents Chemother</source><year>2017</year>; <volume>61</volume>: <comment>e00775-17</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00775-17</pub-id><pub-id pub-id-type="pmcid">PMC5571362</pub-id><pub-id pub-id-type="pmid">28630194</pub-id></mixed-citation></ref><ref id="dkac402-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morgan-Linnell</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Becnel Boyd</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Steffen</surname><given-names>D</given-names></string-name><etal>et al</etal></person-group><article-title>Mechanisms accounting for fluoroquinolone resistance in <italic toggle="yes">Escherichia coli</italic> clinical isolates</article-title>. <source>Antimicrob Agents Chemother</source><year>2009</year>; <volume>53</volume>: <fpage>235</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00665-08</pub-id><pub-id pub-id-type="pmid">18838592</pub-id><pub-id pub-id-type="pmcid">PMC2612180</pub-id></mixed-citation></ref><ref id="dkac402-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vinue</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hooper</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Jacoby</surname><given-names>GA</given-names></string-name></person-group>. <article-title>Chromosomal mutations that accompany qnr in clinical isolates of <italic toggle="yes">Escherichia coli</italic></article-title>. <source>Int J Antimicrob Agents</source><year>2018</year>; <volume>51</volume>: <fpage>479</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.01.012</pub-id><pub-id pub-id-type="pmid">29360506</pub-id><pub-id pub-id-type="pmcid">PMC5849519</pub-id></mixed-citation></ref><ref id="dkac402-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ching</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Orubu</surname><given-names>ESF</given-names></string-name>, <string-name name-style="western"><surname>Sutradhar</surname><given-names>I</given-names></string-name><etal>et al</etal></person-group><article-title>Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones <italic toggle="yes">in vitro</italic>: a systematic review of the literature</article-title>. <source>JAC Antimicrob Resist</source><year>2020</year>; <volume>2</volume>: <comment>dlaa068</comment>. <pub-id pub-id-type="doi">10.1093/jacamr/dlaa068</pub-id><pub-id pub-id-type="pmcid">PMC8210091</pub-id><pub-id pub-id-type="pmid">34223024</pub-id></mixed-citation></ref><ref id="dkac402-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ortiz-Padilla</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Diaz-Diaz</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Machuca</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group><article-title>Role of low-level quinolone resistance in generating tolerance in <italic toggle="yes">Escherichia coli</italic> under therapeutic concentrations of ciprofloxacin</article-title>. <source>J Antimicrob Chemother</source><year>2020</year>; <volume>75</volume>: <fpage>2124</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkaa151</pub-id><pub-id pub-id-type="pmid">32427318</pub-id></mixed-citation></ref><ref id="dkac402-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Leatham-Jensen</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Mokszycki</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Rowley</surname><given-names>DC</given-names></string-name><etal>et al</etal></person-group><article-title>Uropathogenic <italic toggle="yes">Escherichia coli</italic> metabolite-dependent quiescence and persistence may explain antibiotic tolerance during urinary tract infection</article-title>. <source>mSphere</source><year>2016</year>; <volume>1</volume>: <comment>e00055-15</comment>. <pub-id pub-id-type="doi">10.1128/mSphere.00055-15</pub-id><pub-id pub-id-type="pmcid">PMC4863606</pub-id><pub-id pub-id-type="pmid">27303698</pub-id></mixed-citation></ref><ref id="dkac402-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ten Doesschate</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>van Haren</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Wijma</surname><given-names>RA</given-names></string-name><etal>et al</etal></person-group><article-title>The effectiveness of nitrofurantoin, fosfomycin and trimethoprim for the treatment of cystitis in relation to renal function</article-title>. <source>Clin Microbiol Infect</source><year>2020</year>; <volume>26</volume>: <fpage>1355</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2020.03.001</pub-id><pub-id pub-id-type="pmid">32165321</pub-id></mixed-citation></ref><ref id="dkac402-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abbott</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Mouton</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Peleg</surname><given-names>AY</given-names></string-name><etal>et al</etal></person-group><article-title>Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Enterococcus</italic> spp. in an <italic toggle="yes">in vitro</italic> bladder infection model: impact on clinical breakpoints</article-title>. <source>J Antimicrob Chemother</source><year>2021</year>; <volume>76</volume>: <fpage>3201</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkab313</pub-id><pub-id pub-id-type="pmid">34473271</pub-id></mixed-citation></ref><ref id="dkac402-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Beytur</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yakupogullari</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Oguz</surname><given-names>F</given-names></string-name><etal>et al</etal></person-group><article-title>Oral amoxicillin-clavulanic acid treatment in urinary tract infections caused by extended-spectrum beta-lactamase-producing organisms</article-title>. <source>Jundishapur J Microbiol</source><year>2015</year>; <volume>8</volume>: <fpage>e13792</fpage>. <pub-id pub-id-type="doi">10.5812/jjm.13792</pub-id><pub-id pub-id-type="pmid">25763134</pub-id><pub-id pub-id-type="pmcid">PMC4344767</pub-id></mixed-citation></ref><ref id="dkac402-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rodriguez-Bano</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Navarro</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Retamar</surname><given-names>P</given-names></string-name><etal>et al</etal></person-group><article-title>&#946;-Lactam/&#946;-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum &#946;-lactamase-producing <italic toggle="yes">Escherichia coli</italic>: a post hoc analysis of prospective cohorts</article-title>. <source>Clin Infect Dis</source><year>2012</year>; <volume>54</volume>: <fpage>167</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir790</pub-id><pub-id pub-id-type="pmid">22057701</pub-id></mixed-citation></ref><ref id="dkac402-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hooton</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Scholes</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>K</given-names></string-name><etal>et al</etal></person-group><article-title>Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial</article-title>. <source>JAMA</source><year>2005</year>; <volume>293</volume>: <fpage>949</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1001/jama.293.8.949</pub-id><pub-id pub-id-type="pmid">15728165</pub-id></mixed-citation></ref><ref id="dkac402-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Punjabi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tien</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group><article-title>Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs. &#946;-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis</article-title>. <source>Open Forum Infect Dis</source><year>2019</year>; <volume>6</volume>: <comment>ofz364</comment>. <pub-id pub-id-type="doi">10.1093/ofid/ofz364</pub-id><pub-id pub-id-type="pmcid">PMC6785705</pub-id><pub-id pub-id-type="pmid">31412127</pub-id></mixed-citation></ref><ref id="dkac402-B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>Y</given-names></string-name><etal>et al</etal></person-group><article-title>Efficacy and safety of quinolones vs. other antimicrobials for the treatment of uncomplicated urinary tract infections in adults: a systematic review and meta-analysis</article-title>. <source>Int Urogynecol J</source><year>2022</year>; <volume>33</volume>: <fpage>1103</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1007/s00192-021-05013-4</pub-id><pub-id pub-id-type="pmid">34748035</pub-id></mixed-citation></ref><ref id="dkac402-B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stewart</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>PNA</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group><article-title>Oral cephalosporin and &#946;-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections</article-title>. <source>J Antimicrob Chemother</source><year>2020</year>; <volume>75</volume>: <fpage>2384</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkaa183</pub-id><pub-id pub-id-type="pmid">32443141</pub-id></mixed-citation></ref><ref id="dkac402-B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dunne</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Zelasky</surname><given-names>M</given-names></string-name><etal>et al</etal></person-group><article-title>LB-1. Efficacy and safety of oral sulopenem etzadroxil/probenecid versus oral ciprofloxacin in the treatment of uncomplicated urinary tract infections (uUTI) in adult women: results from the SURE-1 trial</article-title>. <source>Open Forum Infect Dis</source><year>2020</year>; <volume>7</volume>: <fpage>S844-S</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofaa515.1898</pub-id></mixed-citation></ref><ref id="dkac402-B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Muir</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Walpole</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Warfel</surname><given-names>PA</given-names></string-name><etal>et al</etal></person-group><article-title>LB-3. Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) &#8211; results from the pivotal ADAPT-PO study</article-title>. <source>Open Forum Infect Dis</source><year>2020</year>; <volume>7</volume>: <fpage>S844</fpage>&#8211;<lpage>S5</lpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofaa515.1900</pub-id></mixed-citation></ref><ref id="dkac402-B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Eckburg</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Muir</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Critchley</surname><given-names>IA</given-names></string-name><etal>et al</etal></person-group><article-title>Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection</article-title>. <source>N Engl J Med</source><year>2022</year>; <volume>386</volume>: <fpage>1327</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2105462</pub-id><pub-id pub-id-type="pmid">35388666</pub-id></mixed-citation></ref><ref id="dkac402-B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Overcash</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Bhiwandi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Garrity-Ryan</surname><given-names>L</given-names></string-name><etal>et al</etal></person-group><article-title>Pharmacokinetics, safety, and clinical outcomes of omadacycline in women with cystitis: results from a phase 1b study</article-title>. <source>Antimicrob Agents Chemother</source><year>2019</year>; <volume>63</volume>: <comment>e02083-18</comment>. <pub-id pub-id-type="doi">10.1128/AAC.02083-18</pub-id><pub-id pub-id-type="pmcid">PMC6496050</pub-id><pub-id pub-id-type="pmid">30858208</pub-id></mixed-citation></ref><ref id="dkac402-B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scangarella-Oman</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Hossain</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hoover</surname><given-names>JL</given-names></string-name><etal>et al</etal></person-group><article-title>Dose selection for phase III clinical evaluation of gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections</article-title>. <source>Antimicrob Agents Chemother</source><year>2022</year>; <volume>66</volume>: <comment>e0149221</comment>. <pub-id pub-id-type="doi">10.1128/aac.01492-21</pub-id><pub-id pub-id-type="pmcid">PMC8923173</pub-id><pub-id pub-id-type="pmid">34978887</pub-id></mixed-citation></ref><ref id="dkac402-B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chatwin</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Hamrick</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Trout</surname><given-names>REL</given-names></string-name><etal>et al</etal></person-group><article-title>Microbiological characterization of VNRX-5236, a broad-spectrum &#946;-lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of Enterobacterales expressing extended-spectrum &#946;-lactamases and serine carbapenemases</article-title>. <source>Antimicrob Agents Chemother</source><year>2021</year>; <volume>65</volume>: <comment>e0055221</comment>. <pub-id pub-id-type="doi">10.1128/AAC.00552-21</pub-id><pub-id pub-id-type="pmcid">PMC8284453</pub-id><pub-id pub-id-type="pmid">34001510</pub-id></mixed-citation></ref><ref id="dkac402-B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Veeraraghavan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bakthavatchalam</surname><given-names>YD</given-names></string-name>, <string-name name-style="western"><surname>Sahni</surname><given-names>RD</given-names></string-name></person-group>. <article-title>Oral antibiotics in clinical development for community-acquired urinary tract infections</article-title>. <source>Infect Dis Ther</source><year>2021</year>; <volume>10</volume>: <fpage>1815</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1007/s40121-021-00509-4</pub-id><pub-id pub-id-type="pmid">34357517</pub-id><pub-id pub-id-type="pmcid">PMC8572892</pub-id></mixed-citation></ref><ref id="dkac402-B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lomovskaya</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Rubio-Aparicio</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tsivkovski</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group><article-title>The ultra-broad-spectrum beta-lactamase inhibitor QPX7728 restores the potency of multiple oral beta-lactam antibiotics against beta-lactamase producing strains of resistant Enterobacterales</article-title>. <source>Antimicrob Agents Chemother</source><year>2022</year>; <volume>66</volume>: <comment>e0216821</comment>. <pub-id pub-id-type="doi">10.1128/AAC.02168-21</pub-id><pub-id pub-id-type="pmcid">PMC8846479</pub-id><pub-id pub-id-type="pmid">34902261</pub-id></mixed-citation></ref><ref id="dkac402-B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Smith</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Ratcliffe</surname><given-names>NT</given-names></string-name></person-group>. <article-title>Effect of pH value and magnesium on the antibacterial activity of quinolone preparations</article-title>. <source>Infection</source><year>1986</year>; <volume>14</volume><issue>Suppl 1</issue>: <fpage>S31</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1007/BF01645195</pub-id><pub-id pub-id-type="pmid">3514470</pub-id></mixed-citation></ref><ref id="dkac402-B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kamberi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tsutsumi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kotegawa</surname><given-names>T</given-names></string-name><etal>et al</etal></person-group><article-title>Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin</article-title>. <source>Antimicrob Agents Chemother</source><year>1999</year>; <volume>43</volume>: <fpage>525</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.43.3.525</pub-id><pub-id pub-id-type="pmid">10049262</pub-id><pub-id pub-id-type="pmcid">PMC89155</pub-id></mixed-citation></ref><ref id="dkac402-B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Drobot</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Karlowsky</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Hoban</surname><given-names>DJ</given-names></string-name><etal>et al</etal></person-group><article-title>Antibiotic activity in microbiological media versus that in human urine: comparison of ampicillin, ciprofloxacin, and trimethoprim-sulfamethoxazole</article-title>. <source>Antimicrob Agents Chemother</source><year>1996</year>; <volume>40</volume>: <fpage>237</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.40.1.237</pub-id><pub-id pub-id-type="pmid">8787914</pub-id><pub-id pub-id-type="pmcid">PMC163091</pub-id></mixed-citation></ref><ref id="dkac402-B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Firsov</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Zinner</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Lubenko</surname><given-names>I</given-names></string-name><etal>et al</etal></person-group><article-title>Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses</article-title>. <source>Int J Antimicrob Agents</source><year>2000</year>; <volume>16</volume>: <fpage>407</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/S0924-8579(00)00226-0</pub-id><pub-id pub-id-type="pmid">11118849</pub-id></mixed-citation></ref><ref id="dkac402-B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vostrov</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Kononenko</surname><given-names>OV</given-names></string-name>, <string-name name-style="western"><surname>Lubenko</surname><given-names>IY</given-names></string-name><etal>et al</etal></person-group><article-title>Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio</article-title>. <source>Antimicrob Agents Chemother</source><year>2000</year>; <volume>44</volume>: <fpage>879</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.44.4.879-884.2000</pub-id><pub-id pub-id-type="pmid">10722485</pub-id><pub-id pub-id-type="pmcid">PMC89786</pub-id></mixed-citation></ref><ref id="dkac402-B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Greenwood</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Baxter</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cowlishaw</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group><article-title>Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis</article-title>. <source>Eur J Clin Microbiol</source><year>1984</year>; <volume>3</volume>: <fpage>351</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/BF01977493</pub-id><pub-id pub-id-type="pmid">6489325</pub-id></mixed-citation></ref><ref id="dkac402-B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nishimura</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kumamoto</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shibuya</surname><given-names>A</given-names></string-name><etal>et al</etal></person-group><article-title>An in vitro study on the treatment of complicated cystitis using an automatic simulator</article-title>. <source>Kansenshogaku Zasshi</source><year>1990</year>; <volume>64</volume>: <fpage>1004</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.11150/kansenshogakuzasshi1970.64.1004</pub-id><pub-id pub-id-type="pmid">2212760</pub-id></mixed-citation></ref><ref id="dkac402-B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jakobsen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Cattoir</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Jensen</surname><given-names>KS</given-names></string-name><etal>et al</etal></person-group><article-title>Impact of low-level fluoroquinolone resistance genes <italic toggle="yes">qnrA1</italic>, <italic toggle="yes">qnrB19</italic> and <italic toggle="yes">qnrS1</italic> on ciprofloxacin treatment of isogenic <italic toggle="yes">Escherichia coli</italic> strains in a murine urinary tract infection model</article-title>. <source>J Antimicrob Chemother</source><year>2012</year>; <volume>67</volume>: <fpage>2438</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dks224</pub-id><pub-id pub-id-type="pmid">22685162</pub-id></mixed-citation></ref><ref id="dkac402-B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reniguntla</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Yedle</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Puttaswamy</surname><given-names>R</given-names></string-name><etal>et al</etal></person-group><article-title>Pharmacokinetics/pharmacodynamics (PK/PD) of ciprofloxacin in the complicated urinary tract infection (cUTI) model in diabetic mice</article-title>. <source>Curr Drug Metab</source><year>2020</year>; <volume>21</volume>: <fpage>132</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2174/1389200221666200310105227</pub-id><pub-id pub-id-type="pmid">32156232</pub-id></mixed-citation></ref><ref id="dkac402-B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murray</surname><given-names>BO</given-names></string-name>, <string-name name-style="western"><surname>Flores</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>C</given-names></string-name><etal>et al</etal></person-group><article-title>Recurrent urinary tract infection: a mystery in search of better model systems</article-title>. <source>Front Cell Infect Microbiol</source><year>2021</year>; <volume>11</volume>: <fpage>691210</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2021.691210</pub-id><pub-id pub-id-type="pmid">34123879</pub-id><pub-id pub-id-type="pmcid">PMC8188986</pub-id></mixed-citation></ref><ref id="dkac402-B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dalhoff</surname><given-names>A</given-names></string-name></person-group>. <article-title>Contribution of immunocompetence to the antibacterial activities of ciprofloxacin and moxifloxacin in an in vitro pharmacodynamic model</article-title>. <source>Infection</source><year>2005</year>; <volume>33</volume><issue>Suppl 2</issue>: <fpage>44</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s15010-005-8207-x</pub-id><pub-id pub-id-type="pmid">16518711</pub-id></mixed-citation></ref><ref id="dkac402-B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Henry</surname><given-names>DC</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Bettis</surname><given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Riffer</surname><given-names>E</given-names></string-name><etal>et al</etal></person-group><article-title>Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women</article-title>. <source>Clin Ther</source><year>2002</year>; <volume>24</volume>: <fpage>2088</fpage>&#8211;<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1016/S0149-2918(02)80099-6</pub-id><pub-id pub-id-type="pmid">12581547</pub-id></mixed-citation></ref><ref id="dkac402-B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fourcroy</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Berner</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Chiang</surname><given-names>YK</given-names></string-name><etal>et al</etal></person-group><article-title>Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women</article-title>. <source>Antimicrob Agents Chemother</source><year>2005</year>; <volume>49</volume>: <fpage>4137</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.49.10.4137-4143.2005</pub-id><pub-id pub-id-type="pmid">16189090</pub-id><pub-id pub-id-type="pmcid">PMC1251530</pub-id></mixed-citation></ref><ref id="dkac402-B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Talan</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Klimberg</surname><given-names>IW</given-names></string-name>, <string-name name-style="western"><surname>Nicolle</surname><given-names>LE</given-names></string-name><etal>et al</etal></person-group><article-title>Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis</article-title>. <source>J Urol</source><year>2004</year>; <volume>171</volume>: <fpage>734</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/01.ju.0000106191.11936.64</pub-id><pub-id pub-id-type="pmid">14713799</pub-id></mixed-citation></ref><ref id="dkac402-B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Talan</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Naber</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Palou</surname><given-names>J</given-names></string-name><etal>et al</etal></person-group><article-title>Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections</article-title>. <source>Int J Antimicrob Agents</source><year>2004</year>; <volume>23</volume><issue>Suppl 1</issue>: <fpage>S54</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2003.12.005</pub-id><pub-id pub-id-type="pmid">15037329</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>